var title_f23_63_24560="Kroener fimbriectomy";
var content_f23_63_24560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kroener fimbriectomy sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24560=[""].join("\n");
var outline_f23_63_24560=null;
var title_f23_63_24561="Hyperacute rejection IF Fibrin";
var content_f23_63_24561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection with fibrin by immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in hyperacute rejection showing extensive fibrin deposition in a glomerulus (right) and in the vascular wall and lumen of an artery (left). The arterial lumen is markedly narrowed due to intraluminal fibrin deposition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24561=[""].join("\n");
var outline_f23_63_24561=null;
var title_f23_63_24562="Didelphus uterus";
var content_f23_63_24562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Didelphus uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two cervices are easily visualized in this hysterectomy specimen. Both tubes and ovaries are present, as well as an intraligamentous leiomyoma (right side of photograph).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robert MLellan, MD and Aron Schuftan, MD; Lahey Clinic Foundation. Copyright &copy; Robert McLellan, MD and Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24562=[""].join("\n");
var outline_f23_63_24562=null;
var title_f23_63_24563="Pinguecula";
var content_f23_63_24563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pinguecula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24563=[""].join("\n");
var outline_f23_63_24563=null;
var title_f23_63_24564="Levofloxacin (ophthalmic): Patient drug information";
var content_f23_63_24564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levofloxacin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=see_link\">",
"     see \"Levofloxacin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5299?source=see_link\">",
"     see \"Levofloxacin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iquix&reg;;",
"     </li>",
"     <li>",
"      Quixin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695332",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you have the right liquid; there is more than one strength.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12238 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24564=[""].join("\n");
var outline_f23_63_24564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398379\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024256\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024255\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024260\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024261\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024263\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024258\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024259\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024264\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024265\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_63_24565="COPD pressure flow muscle";
var content_f23_63_24565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    COPD pressure, flow, and muscle tracings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 537px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recordings of flow, airway pressure (Paw), and transversus abdominis electromyography in a critically ill patient with COPD who is receiving pressure support of 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. The onset of expiratory muscle activity (vertical dotted line) occurred when mechanical inflation was only partially completed, indicating that the patient was \"fighting the ventilator\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parthasarathy S, Jubran A, Tobin MJ. Am J Respir Crit Care Med 1998; 158:1471. Copyright &copy;1998 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24565=[""].join("\n");
var outline_f23_63_24565=null;
var title_f23_63_24566="Nitrates in the management of acute coronary syndrome";
var content_f23_63_24566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nitrates in the management of acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24566/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/63/24566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual, intravenous, and oral nitrate preparations are used in the management of acute coronary syndromes. Most of the published data come from patients with myocardial infarction (MI), but the conclusions would apply to patients with unstable angina.",
"   </p>",
"   <p>",
"    Benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilatation of large coronary arteries and arterioles (&gt;100 millimicrons in diameter), which may lead to increased perfusion of ischemic zones.",
"     </li>",
"     <li>",
"      Dilatation of the venous system with decreased preload, reduction in ventricular volume, and a fall in pulmonary capillary wedge pressure. This effect is useful in patients with pulmonary congestion.",
"     </li>",
"     <li>",
"      Systemic arterial dilatation, which decreases afterload, also occurs but to a lesser degree. These changes lower wall stress and oxygen consumption and can reverse a restrictive filling pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction of infarct size in experimental animal studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Termination of an episode of variant angina. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"       \"Variant angina\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enhanced collateral blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nitrates produce these effects by entering vascular smooth muscle cells and combining with sulfhydryl groups to form nitric oxide and eventually S-nitrosothiols (",
"    <a class=\"graphic graphic_figure graphicRef50622 \" href=\"UTD.htm?10/21/10590\">",
"     figure 1",
"    </a>",
"    ). The nitrosothiols stimulate guanylate cyclase to produce cyclic guanosine monophosphate (cGMP), which causes smooth muscle relaxation by decreasing intracellular calcium levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H2#H2\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of nitrates in the management of acute MI, which includes ST elevation and non-ST elevation MI, will be reviewed here. The role of nitrate therapy in patients in the emergency department suspected of having chest pain due to myocardial ischemia and the overall management of the patient with an MI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Immediate ED interventions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND CAUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary adverse effects induced by nitrate therapy include hypotension (especially in patients with ventricular ischemia or hypovolemia), headache, and tachycardia. Hypovolemia or nitrate-induced hypotension respond promptly to volume replacement. Despite presumed correction of preload by the infusion of saline, the antiischemic effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    persists.",
"   </p>",
"   <p>",
"    Prolonged infusion of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    may lead to the development both of methemoglobinemia (which can be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    ) and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    resistance. In addition, commercial preparations of intravenous nitroglycerin contain alcohol (0.01 to 0.14",
"    <span class=\"nowrap\">",
"     mL/mg",
"    </span>",
"    of nitroglycerin). Thus, a substantial alcohol load may be delivered to the patient.",
"   </p>",
"   <p>",
"    Nitrates in all forms should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure less than 90 mmHg or &ge;30 mmHg below baseline. Nitrates may induce symptomatic hypotension and can lead to hemodynamic decompensation in the setting of cardiac ischemia.",
"     </li>",
"     <li>",
"      Marked bradycardia (heart rate less than 50 beats per minute) or tachycardia (heart rate greater than 100 beats per minute). In this setting nitrates may cause hemodynamic decompensation.",
"     </li>",
"     <li>",
"      Known or suspected right ventricular infarction. Nitrates should be avoided because of the increased risk of inducing hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have taken a phosphodiesterase inhibitor for erectile dysfunction within the last 24 hours (or perhaps as long as 48 hours with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      ). Nitrates may induce severe hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"       \"Sexual activity in patients with heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy. Nitrates can induce or increase outflow tract obstruction, even in those not known to have a resting gradient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe aortic stenosis. A sudden decrease in blood pressure can lead to cardiovascular collapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In view of their marginal treatment benefits, nitrates should not be used in preference to beta blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    for the management of refractory chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, the chronic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should not preclude therapy with beta blockers and angiotensin converting enzyme inhibitors. The latter drugs improve survival, a benefit not seen with nitroglycerin. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'GISSI-3 trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUBLINGUAL NITROGLYCERIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is the therapy of choice for acute anginal episodes and for prophylaxis of activities known to elicit angina. It is administered to the patient with acute MI to improve symptoms, lower blood pressure, improve pulmonary congestion, and, in some cases, to help in the diagnosis of coronary artery spasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link&amp;anchor=H19#H19\">",
"     \"Variant angina\", section on 'Nitrates and calcium channel blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the patient presenting to the emergency department with chest pain that may be due to cardiac ischemia, sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is commonly administered at a dose of 0.4 mg every five minutes for a total of three doses. One-half the dose (0.15 mg) can be used if the patient becomes hypotensive or develops symptoms such as headache or flushing with the higher doses. Up to 0.6 mg may be given to patients with refractory angina, particularly those with hypertension. After the administration of sublingual nitroglycerin, assessment should be made about the need for intravenous nitroglycerin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTRAVENOUS NITROGLYCERIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is typically initiated in patients with persistent ischemic chest pain despite three sublingual nitroglycerin tablets and other adjunctive therapies, such as supplemental oxygen and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive clinical use, there is remarkably little objective information documenting the effectiveness of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in unstable angina. Several small trials have evaluated the ability of an open-label infusion of nitroglycerin to reduce the frequency of ischemic chest pain; symptomatic relief was noted in each of the reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. One randomized trial of 167 patients found that, compared to placebo, intravenous nitroglycerin reduced the frequency and duration of ischemic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, a single randomized trial compared the intravenous, oral, and transdermal nitroglycerin preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/8\">",
"     8",
"    </a>",
"    ]. There was no difference in response among the preparations with regard to symptomatic improvement. However, the small size of this study (40 patients) makes it difficult to draw definitive conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     GISSI-3 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the third Gruppo Italiano per lo Studio dell Sopravvivenza nell'Infarto Miocardico (GISSI-3), 19,394 patients with acute MI between 1991 and 1993 were randomly assigned in a two-by-two factorial design to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    followed by a nitrate patch or placebo, as well as to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/9\">",
"     9",
"    </a>",
"    ]. Intravenous nitroglycerin was infused within the first 24 hours, starting at 5",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    and increasing until the systolic blood pressure fell by 10 percent, avoiding systolic pressure below 90 mmHg. Nitrate patch and lisinopril were maintained for six weeks and the patients were followed for six months from the date of randomization.",
"   </p>",
"   <p>",
"    The results were analyzed by intention to treat; however, 57 percent of the placebo group received short-term nitrate therapy for angina or heart failure and approximately 11 percent received long-term nitrate therapy. Most of the patients were treated with other appropriate therapies for MI at the time of the trial such as thrombolysis (72 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (84 percent), and beta blockers (31 percent).",
"   </p>",
"   <p>",
"    The primary study end point of mortality at six weeks demonstrated",
"    <strong>",
"     no significant benefit",
"    </strong>",
"    of nitrate therapy. However, the subset of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    and nitrates had the lowest mortality in the trial (odds ratio 0.83 versus 0.88 for lisinopril alone), suggesting a possible additive beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    to lisinopril. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nitrate patch was discontinued at six weeks. Six month follow-up continued to show no difference in mortality (18.4 versus 18.9 percent) or left ventricular dysfunction in the patients who received nitrate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on STEMI suggested the following approach to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/4\">",
"     4",
"    </a>",
"    ]. No changes to this approach were made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intravenous infusion permits titration of therapy according to the blood pressure response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      therapy is relief of symptoms or a mean arterial blood pressure 10 percent below baseline in normotensive patients and up to 25 to 30 percent in hypertensive patients. The blood pressure lowering should be gradual with careful attention to signs or symptoms of hypoperfusion. The systolic pressure should not fall below 90 mmHg or by more than 30 mmHg.",
"     </li>",
"     <li>",
"      The initial infusion rate is 5 to 10",
"      <span class=\"nowrap\">",
"       &micro;g/min.",
"      </span>",
"     </li>",
"     <li>",
"      If the above goals are not met, the infusion rate is gradually increased at approximately 10 minute intervals by 5 to as much as 20",
"      <span class=\"nowrap\">",
"       &micro;g/min.",
"      </span>",
"     </li>",
"     <li>",
"      In general, the dose should not exceed 400",
"      <span class=\"nowrap\">",
"       &micro;g/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The infusion is indicated in the first 48 hours for persistent ischemia, heart failure, or hypertension. Intravenous, oral, or topical nitrates can be given after 48 hours for recurrent of persistent indications. At any time, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should not preclude therapy with beta blockers and angiotensin converting enzyme inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nitrate tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major concern with a continuous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is the development of nitrate tolerance that occurs in most patients within 24 hours. In GISSI-3, for example, the blood pressure lowering effect of intravenous nitroglycerin was lost within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/9\">",
"     9",
"    </a>",
"    ]. However, prolonged nitroglycerin infusions are not generally needed in acute coronary syndromes, since patients with ST elevation are either rapidly given fibrinolytic therapy or taken directly to the catheterization laboratory, while many patients with non-ST elevation acute coronary syndromes go to the catheterization laboratory within the first 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H6#H6\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Nitrate tolerance'",
"    </a>",
"    .) (See appropriate topic reviews on fibrinolytic therapy and percutaneous coronary intervention in acute coronary syndromes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ORAL AND TRANSDERMAL NITRATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As most patients with acute coronary syndrome undergo revascularization during the index hospitalization, oral nitrates are rarely prescribed for the purpose of either preventing or managing angina. However, outpatient oral nitrates may be appropriate in the minority of patients who do not attain complete relief of angina after revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H9#H9\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Commonly used nitrate preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , there is no evidence that oral nitrate therapy after acute coronary syndrome reduces mortality. This issue was evaluated in the ISIS-4 trial. Longer-term nitrate therapy may help to prevent left ventricular remodeling, but ACE inhibitors are likely to be more effective for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ISIS-4 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fourth Internal Study of Infarct Survival (ISIS-4) examined the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , and intravenous magnesium sulphate in 58,050 patients presenting with a suspected acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/12\">",
"     12",
"    </a>",
"    ]. The trial design was a two-by-two-by-two factorial, and an oral mononitrate (60 mg) was utilized with placebo group comparison. The primary end point was 35-day mortality. Nitrates were not withheld from patients in the control group with appropriate clinical indications, including ischemic chest pain and heart failure. Thus, similar to GISSI-3 described above for intravenous nitroglycerin, there was substantial nonprotocol use of nitrates as 54 percent of control patients received intravenous nitroglycerin and 6 percent some other nonstudy nitrate.",
"   </p>",
"   <p>",
"    There was no significant reduction in mortality (7.3 versus 7.5 percent with placebo) at 35 days, and follow-up at 12 months did not indicate any late survival advantage. Critics of ISIS-4 have cited the low dose of mononitrate which, at least in some studies, has been shown to be relatively ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates used for this purpose include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (starting at 10 mg three times daily and increasing to 40 mg three times daily as necessary, given at 8 AM, 1 PM, and 6 PM),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    (starting at 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the morning and increasing to 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as necessary), or a transdermal nitroglycerine patch (starting at 0.2",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    and increasing to 0.6",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    with removal of the patch at 6 to 8 PM). These regimens provide an adequate nitrate-free interval to prevent complete nitrate tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H6#H6\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Nitrate tolerance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term nitrate therapy is associated with a modest hemodynamic benefit in patients with a low left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24566/abstract/14\">",
"     14",
"    </a>",
"    ]. However, in the era of ACE inhibitors and angiotensin II receptor blockers, nitrate therapy for this purpose would be considered only in patients unable to take an angiotensin inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrate therapy has an important role in the management of patients with an acute coronary syndrome, despite the absence of a mortality benefit. It can be of value in reducing or potentially eliminating pain (either initial or recurrent) due to myocardial ischemia, improving symptoms of pulmonary congestion, lowering blood pressure in hypertensive patients, and aiding in the diagnosis and management of the rare patient who presents with variant angina (coronary artery spasm).",
"   </p>",
"   <p>",
"    Nitrates are part of combined modality therapy for chest pain, myocardial ischemia, heart failure and hypertension in the patient with an acute coronary syndrome. As an example, chest pain is better managed with opioid analgesic agents and myocardial ischemia is treated with oxygen, beta blockers, and early reperfusion therapy with fibrinolysis or percutaneous coronary intervention. Similarly, pulmonary congestion often requires the combination of diuretics, nitrates, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    , while the lowering of blood pressure can be achieved with the combined use of beta blockers, nitrates, and anxiolytic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several important adverse effects of nitrate therapy. Avoid nitrates in patients with systolic blood pressure &lt;90 mmHg or &ge;30 mmHg below baseline, marked bradycardia or tachycardia, known or suspected right ventricular infarction, phosphodiesterase inhibitor use within the last 24 to 48 hours, hypertrophic cardiomyopathy, or severe aortic stenosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Side effects and caution'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of hypotension in patients with volume depletion, right ventricular infarction, or recent use of a phosphodiesterase inhibitor for erectile dysfunction (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The prevention of optimal dosing of beta blockers or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      due to its blood pressure lowering effect.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/1\">",
"      Garadah T, Ghaisas NK, Mehana N, et al. Impact of intravenous nitroglycerin on pulsed Doppler indexes of left ventricular filling in acute anterior myocardial infarction. Am Heart J 1998; 136:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/2\">",
"      Jugdutt BI, Becker LC, Hutchins GM, et al. Effect of intravenous nitroglycerin on collateral blood flow and infarct size in the conscious dog. Circulation 1981; 63:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/3\">",
"      Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988; 78:906.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/5\">",
"      DePace NL, Herling IM, Kotler MN, et al. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med 1982; 142:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/6\">",
"      Kaplan K, Davison R, Parker M, et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol 1983; 51:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/7\">",
"      Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med 1998; 243:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/8\">",
"      Curfman GD, Heinsimer JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial. Circulation 1983; 67:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/9\">",
"      GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/10\">",
"      Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996; 27:337.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/12\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     Thadani U, Opie LH. Nitrates. In: Drugs for the Heart, 4th ed, Opie LH (Ed), Saunders, Philadelphia 1995. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24566/abstract/14\">",
"      Mahmarian JJ, Moy&eacute; LA, Chinoy DA, et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998; 97:2017.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 64 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-E4F9E9D48D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24566=[""].join("\n");
var outline_f23_63_24566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SIDE EFFECTS AND CAUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUBLINGUAL NITROGLYCERIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTRAVENOUS NITROGLYCERIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - GISSI-3 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nitrate tolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ORAL AND TRANSDERMAL NITRATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ISIS-4 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/64\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/64|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/21/10590\" title=\"figure 1\">",
"      Nitrate induced vasodilation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_63_24567="Combitube insertion";
var content_f23_63_24567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Mallinckrodt esophageal tracheal airway double lumen (Combitube) insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. Lubricate and insert the Combitube until the double black line is located in between the teeth. B. Inflate the blue pharyngeal cuff and white pilot balloons. C. Attach bag-valve-mask to the blue connector and assess for lung sounds and chest wall movement. Pass a gastric tube through the white distall connector and confirm suction of gastric contents. D. If&nbsp;breath sounds and chest wall movement are absent or decreased, the distal balloon may be in the trachea. Place &nbsp;the bag-valve-mask on the connector for the white distal balloon and ventilate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image used by permission from: Nellcor Puritan Bennett LLC, Boulder, Colorado, doing business as Covidien. Illustration originally published in: King BR, Hagberg CA. Management of the difficult airway. In: The Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24567=[""].join("\n");
var outline_f23_63_24567=null;
var title_f23_63_24568="Initial risk-stratified treatment for advanced testicular germ cell tumors";
var content_f23_63_24568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial risk-stratified treatment for advanced testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24568/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24568/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/63/24568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers are one of the most curable solid neoplasms. As an example, in the United States, the five-year survival rate is over 95 percent, and fewer than 400 deaths from testicular cancer are seen per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that have likely contributed to the declining mortality rate from testicular cancer include the development and use of effective chemotherapy, a trend toward earlier stage disease at presentation, and an increasing proportion of tumors that are pure seminomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with visceral metastases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    highly elevated serum tumor markers are considered to have advanced germ cell tumors (GCTs). For these men,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy is used with curative intent. There is a delicate balance between too little and too much therapy in men with GCTs. Inadequate therapy can cause a missed opportunity for cure and an unnecessary patient death. On the other hand, the cure rates are so high with intensive therapy that there is a risk of overtreatment, with its associated acute and delayed toxicities. Whenever possible, men with advanced testicular germ cell tumors should be referred to centers with expertise in the management of such tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike the approach to early-stage testicular cancers, the treatment of advanced GCTs is guided using risk stratification and less so by histologic type. However, the histologic variant of GCT (seminoma versus nonseminomatous GCT) has both prognostic implications and informs follow-up of testicular cancer survivors.",
"   </p>",
"   <p>",
"    The risk stratification of advanced testicular GCTs and initial management based on risk will be reviewed here. The clinical manifestations, diagnosis, and staging, an overview of the approach, surgical treatment, and the approach to early stage testicular GCTs are reviewed separately. In addition, chemotherapy protocols used in the management of GCTs are also covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"       \"Overview of the treatment of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"       \"Treatment of stage I seminoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"       \"Management of stage I nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"       \"Treatment of stage II seminoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"       \"Management of stage II nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19858?source=see_link\">",
"       \"Treatment protocols for germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494225\">",
"    <span class=\"h1\">",
"     DEFINITION OF RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1997 joint staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (IUCC) (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"     table 3",
"    </a>",
"    ) is used to stage men with testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. For men with advanced disease, it is supplemented with a validated prognostic model that was developed by the International Germ Cell Cancer Collaborative Group (IGCCCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the IGCCCG prognostic classification system, patients are divided into good-, intermediate-, and poor-risk groups for both progression-free and overall survival (",
"    <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It is based upon the primary site of the germ cell tumor (GCT), metastatic sites of involvement, and levels of serum tumor markers (drawn on day 1 of the first cycle, prior to initiation of chemotherapy).",
"   </p>",
"   <p>",
"    The risk stratification system is important to identify appropriate treatment for men with GCTs. Risk stratification differs for seminomas and nonseminomatous germ cell tumors (NSGCT) and is reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494364\">",
"    <span class=\"h2\">",
"     Seminomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic seminomas are classified as either good- or intermediate-risk, based upon whether or not metastases to organs other than the lungs or lymph nodes are present. Serum levels of beta-human chorionic gonadotropin (&beta;-hCG) and lactate dehydrogenase (LDH) are not used in assigning risk status to patients with seminoma, although one or both are often elevated.",
"   </p>",
"   <p>",
"    Men with a pathologic diagnosis of seminoma, but with a highly elevated &beta;-hCG (eg, &beta;-hCG &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    or any elevation of AFP are considered to have a NSGCT, even if other histologic elements are not identified on pathologic review. (See",
"    <a class=\"local\" href=\"#H547494385\">",
"     'Nonseminomatous germ cell tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Criteria used to define good- and intermediate-risk for men with advanced seminoma are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494371\">",
"    <span class=\"h3\">",
"     Good risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of men with advanced seminoma have good-risk disease and have an excellent prognosis following orchiectomy alone. In the 1997 publication that established these criteria, the five-year progression-free (PFS) and overall survival (OS) rates were 90 and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with metastatic seminomas are classified as good risk if all of the following criteria are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any primary site",
"     </li>",
"     <li>",
"      No metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Normal serum AFP",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494378\">",
"    <span class=\"h3\">",
"     Intermediate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of men with seminoma had intermediate-risk disease. Their five-year PFS and OS rates were 67 and 72 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with metastatic seminomas are classified as intermediate risk if all of the following criteria are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any primary site",
"     </li>",
"     <li>",
"      Metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes are present",
"     </li>",
"     <li>",
"      Normal serum AFP",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494385\">",
"    <span class=\"h2\">",
"     Nonseminomatous germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with metastatic NSGCT are also divided into good- and intermediate-risk categories, similar to seminomas. However, a third category of men with NSGCT are classified as having poor-risk disease.",
"   </p>",
"   <p>",
"    Stratification is based upon the primary site of the tumor, the extent and location of metastatic disease, and the degree of elevation of serum tumor markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494392\">",
"    <span class=\"h3\">",
"     Good risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 56 percent of men have good-risk metastatic NSGCT. The five-year PFS and OS rates for these patients are 89 and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with metastatic NSGCTs are categorized as good risk if they meet all of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular or retroperitoneal primary tumor",
"     </li>",
"     <li>",
"      No extrapulmonary (ie, visceral) metastases",
"     </li>",
"     <li>",
"      Tumor markers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum AFP &lt;1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      &beta;-hCG &lt;5000 international",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"     </li>",
"     <li>",
"      Lactate dehydrogenase (LDH) &lt;1.5 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494399\">",
"    <span class=\"h3\">",
"     Intermediate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermediate-risk NSGCTs comprises 28 percent of patients. The five-year PFS and OS rates are 75 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ]. Intermediate-risk patients with NSGCTs if all of the following criteria are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular or retroperitoneal primary tumor",
"     </li>",
"     <li>",
"      No metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Tumor markers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum AFP 1000 to 10,000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      &beta;-hCG 5000 to 50,000 international",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      or",
"     </li>",
"     <li>",
"      LDH 1.5 to 10 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547494406\">",
"    <span class=\"h3\">",
"     Poor risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 16 percent of men with NSGCT have poor-risk disease. The five-year PFS and OS rates for these patients are 41 and 48 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with nonseminomatous GCTs are considered poor risk if",
"    <strong>",
"     any",
"    </strong>",
"    of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mediastinal primary site with or without metastases (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extrapulmonary (ie, visceral) metastases (eg, liver or brain metastases)",
"     </li>",
"     <li>",
"      Tumor markers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum AFP &gt;10,000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      &beta;-hCG &gt;50,000 international",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      or",
"     </li>",
"     <li>",
"      LDH &gt;10 times the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1195404\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the approach to early stage GCT, the treatment of advanced disease depends on the prognostic risk group rather than on histologic type alone. However, the type of GCT has prognostic implications and helps to inform appropriate follow-up at the end of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link&amp;anchor=H7#H7\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Guidelines for follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Good-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with good-risk advanced GCT, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination therapy. We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and cisplatin (BEP) rather than etoposide plus cisplatin (EP) in most patients, although both are acceptable regimens. For men at risk for pulmonary toxicity from bleomycin, we prefer EP. If BEP is used, we recommend three rather than four cycles. However, if EP is administered, we recommend four cycles.",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10825925\">",
"    <span class=\"h3\">",
"     Blemoycin, etoposide, and cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with good-risk GCTs, we suggest three cycles of standard BEP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    30 units on days 1, 8, and 15;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 5;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 5) administered on a 21-day cycle. This regimen of BEP is associated with an excellent survival outcome with limited toxicity (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Three cycles of standard BEP results in similar activity and less toxicity compared to four cycles of BEP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. This was demonstrated in a randomized phase III trial conducted by the Southeastern Cancer Study Group, in which 184 men with good-risk advanced testicular GCT were randomly assigned to either three or four cycles of BEP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/5\">",
"     5",
"    </a>",
"    ]. With a minimal follow-up of one year, the rate of complete remission was 98 and 97 percent following three and four cycles of BEP, respectively. These results were confirmed in a 2008 systematic review, which reported that approximately 90 percent of men with good-risk GCT had a durable complete remission to either regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    For men receiving BEP, dose intensity should be maintained throughout treatment because lowered chemotherapy doses are associated with worse outcomes. In a trial sponsored by the Australian and New Zealand Germ Cell Trial Group, 166 men were randomly assigned treatment using three cycles of standard BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ) or four cycles of a modified BEP regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , 30 units",
"    <strong>",
"     day 1",
"    </strong>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , 120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    <strong>",
"     days 1 to 3",
"    </strong>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    <strong>",
"     day 1",
"    </strong>",
"    ) every 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/7\">",
"     7",
"    </a>",
"    ]. The trial was closed at interim analysis because the modified BEP arm was inferior to standard BEP. Compared to modified BEP dosing, standard BEP dosing was associated with significant improvement in overall survival (hazard ratio for mortality 0.25, 95% CI 0.07-0.88).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10826096\">",
"    <span class=\"h3\">",
"     Etoposide and cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the association of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    with occasional but serious (and potentially fatal) pulmonary toxicity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EP) for four cycles has been evaluated as an alternative regimen to BEP. While we prefer BEP as first-line therapy in men with good-risk GCT, the available evidence suggest that EP is a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/4\">",
"     4",
"    </a>",
"    ]. These data are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       EORTC Trial",
"      </strong>",
"      &mdash; The European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group conducted a study of 395 men who were randomly assigned to treatment using four cycles of EP with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , with a lower dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      administered than what is now considered standard (360",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per cycle rather than the standard 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per cycle) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/8\">",
"       8",
"      </a>",
"      ]. Compared to EP, BEP resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly higher complete response rate (95 versus 87 percent with EP, p&lt;0.008)",
"     </li>",
"     <li>",
"      Significantly higher rates of pulmonary toxicity and neurotoxicity",
"     </li>",
"     <li>",
"      More treatment-related deaths (12 versus 7 patients), though this difference was not statistically significant (p=0.26)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       GETUG T93BP",
"      </strong>",
"      &mdash; In this randomized trial conducted by the Genitourinary Group of the French Federation of Cancer Centers, 257 men were assigned to BEP for three cycles or EP for four cycles (using standard doses) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/9\">",
"       9",
"      </a>",
"      ]. The overall response rate was equivalent between EP and BEP (97 versus 96 percent, respectively). At a median follow-up of 53 months, EP was associated with a lower four year event-free survival rate (86 versus 91 percent, p=0.135) and more men died during follow-up (12 versus 5 men, p=0.096), though neither result was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that EP (four cycles) results in similar outcomes in the treatment of good-risk testicular GCT. However, we suggest administration of BEP rather than EP for men with good risk GCT. We reserve four cycles of EP for men with compromised pulmonary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Is there a role for carboplatin?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the improved toxicity profile associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , we do not recommend substitution of carboplatin for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    because it is associated with decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest trial, four cycles of modified BEP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    30 units on day 2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day on days 1 to 5, or 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 2), administered every three weeks, was compared to four cycles of CEB (bleomycin 30 units on day 2, etoposide 120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , dosed at an area under the concentration x time curve [AUC] 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/11\">",
"     11",
"    </a>",
"    ]. The cisplatin combination was associated with significantly enhanced rates of three-year overall survival (97 versus 90 percent with the carboplatin regimen) and one-year failure-free survival (91 versus 77 percent).",
"   </p>",
"   <p>",
"    In a separate trial, men were randomly assigned to three cycles of standard dose BEP to four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    . The trial was terminated after 54 patients were accrued due to a higher relapse rate (32 versus 13 percent) and a larger number of deaths (four versus one) in the carboplatin arm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chemotherapy-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with good-risk disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is generally well tolerated. Almost all patients will experience myelosuppression (particularly neutropenia), fatigue, hair loss, and at least mild-to-moderate nausea.",
"   </p>",
"   <p>",
"    Full doses should be administered at the scheduled time, regardless of the white blood cell count on day 1 of each cycle, to maximize the chances for cure. The risk of neutropenic fever and fatal infections is low in patients with good-risk disease. Therefore, for good-risk patients, we recommend use of granulocyte colony stimulating factors (G-CSF) only if the prior cycle was complicated by febrile neutropenia. When the prior cycle was complicated by febrile neutropenia or some other significant clinical event, a delay in treatment is recommended if necessary to allow the patient to recover. For example, for a patient with febrile neutropenia, additional chemotherapy should be delayed until the neutropenia has resolved and any identified infection is under control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intermediate- and poor-risk advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with intermediate- or poor risk disease, we recommend four cycles of BEP rather than other platinum-based regimens. There is no data to support the use of three rather than four cycles of BEP in this population. In addition, there are no data supporting the use of more than four cycles. &nbsp;",
"   </p>",
"   <p>",
"    The benefit of BEP was demonstrated in a trial involving 244 men with advanced GCT randomly assigned treatment with BEP versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (PVB) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared to PVB, BEP resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly higher complete response rate (77 versus 66 percent) among men with advanced disease (defined by the presence of extensive pulmonary disease, abdominal or visceral metastases, central nervous system, bone or extra-abdominal nodal involvement) &nbsp;",
"     </li>",
"     <li>",
"      Similar overall survival at two years (80 percent in each arm)",
"     </li>",
"     <li>",
"      Significantly less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity, including paresthesias (4 versus 11 percent), abdominal cramps (2 versus 8 percent), and myalgias (0 versus 14 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although four courses of BEP remains the standard of care for men with intermediate- or poor-risk disease, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (VIP) is an alternative to BEP in men who are not candidates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . This includes men with [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underlying lung disease",
"     </li>",
"     <li>",
"      Bulky lung disease that may require post-chemotherapy resection (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H1146316108#H1146316108\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'Preoperative considerations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extensive tumor burden in the lung",
"     </li>",
"     <li>",
"      Men with primary mediastinal nonseminomatous germ cell tumors (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data to support the use of VIP come from the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intergroup Trial &mdash; In this trial, 299 men with poor-risk disease were randomly assigned to four cycles of either BEP or VIP [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/15\">",
"       15",
"      </a>",
"      ]. Compared to BEP, VIP resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar complete remission rate (37 versus 31 percent, respectively)",
"     </li>",
"     <li>",
"      A similar two-year rate of failure free (64 versus 60 percent) and overall (74 versus 71 percent) survival",
"     </li>",
"     <li>",
"      Significantly higher rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity (88 versus 73 percent)",
"     </li>",
"     <li>",
"      With longer follow-up, no significant differences were seen for men with poor-risk disease in either progression-free survival (56 versus 49 percent) or overall survival (62 and 57 percent for VIP and BEP, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A second, smaller trial included 84 men with intermediate-risk disease randomly assigned to treatment with VIP or BEP [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/17\">",
"       17",
"      </a>",
"      ]. Compared to BEP, VIP resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar complete response rate (74 versus 79 percent)",
"     </li>",
"     <li>",
"      Similar rate of progression free survival at five years (85 versus 83 percent)",
"     </li>",
"     <li>",
"      Significantly higher rate of grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      leukopenia (89 versus 37 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other therapeutic approaches for poor-risk disease have included escalation of the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , dose intensification through the use of sequential or alternating non-cross-resistant chemotherapy regimens, and the use of high-dose chemotherapy protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/18-35\">",
"     18-35",
"    </a>",
"    ]. At this time, none of these approaches have demonstrated superiority to BEP in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24568/abstract/36\">",
"     36",
"    </a>",
"    ]. Therefore, we do not recommend their use in men with intermediate- or poor-risk advanced GCT. However, we do encourage eligible men to enroll in clinical trials evaluating new treatment strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29429295\">",
"    <span class=\"h3\">",
"     Chemotherapy-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with intermediate and poor-risk disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is associated with a greater risk of both neutropenic sepsis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    pneumonitis compared to men with good-risk disease, both of which can be fatal. Almost all patients will experience myelosuppression (particularly neutropenia), fatigue, hair loss, and at least mild-to-moderate nausea and there is a significant rate of peripheral neuropathy, high-frequency hearing loss, and decline in measured renal and pulmonary function.",
"   </p>",
"   <p>",
"    Despite these concerns, full doses should be administered at the scheduled time, regardless of the white blood cell count on day one of each cycle, to maximize the chances for cure. Given the substantial risk of neutropenic fever and fatal infections in intermediate- and poor-risk patients, we suggest administration of G-CSF prior to each cycle (ie, prophylactically). When the prior cycle was complicated by febrile neutropenia or some other significant clinical event, a delay in treatment is recommended if necessary to allow the patient to recover.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular cancers, 95 percent of which are germ cell tumors (GCTs), have become one of the most curable solid neoplasms because of remarkable treatment advances, with an expected five-year survival rate over 95 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with advanced germ cell tumors (GCTs), stratification into good-, intermediate-, or poor-risk categories, based upon their histology, primary tumor site, anatomic staging, and levels of serum markers, is necessary prior to treatment (",
"      <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H547494225\">",
"       'Definition of risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at normal risk of lung toxicity and with good risk, we suggest chemotherapy with three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (BEP) (",
"      <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"       table 4",
"      </a>",
"      ) rather than four cycles of EP (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, for men with good risk GCTs who are at risk of bleomycin lung toxicity, we suggest four cycles of chemotherapy with etoposide and cisplatin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Good-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      as a substitute for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      in the treatment of testicular GCTs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Is there a role for carboplatin?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with intermediate- or poor-risk GCTs, we recommend four cycles of BEP rather than other",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combinations (",
"      <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For those at a significantly increased risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      lung toxicity, we suggest four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and cisplatin (VIP) as an alternative regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intermediate- and poor-risk advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with intermediate- or poor-risk GCT receiving four cycles of BEP or VIP, we recommend the administration of prophylactic granulocyte colony stimulating factors (G-CSF) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, we do not administer prophylactic G-CSF for men with good-risk GCTs receiving three cycles of BEP.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/1\">",
"      Powles TB, Bhardwa J, Shamash J, et al. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 2005; 95:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/2\">",
"      International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     Testis. In: AJCC Cancer Staging Handbook, 6th, Green FL, Page DL, Fleming ID, et al (Eds), Springer Verlag, New York 2002. p.347.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/4\">",
"      Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/5\">",
"      Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/6\">",
"      Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998; 16:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/7\">",
"      Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001; 357:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/8\">",
"      de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/9\">",
"      Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/10\">",
"      Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/11\">",
"      Horwich A, Sleijfer DT, Foss&aring; SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/12\">",
"      Bokemeyer C, K&ouml;hrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/13\">",
"      Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/14\">",
"      Massard C, Plantade A, Gross-Goupil M, et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 2010; 21:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/15\">",
"      Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/16\">",
"      Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003; 97:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/17\">",
"      de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/18\">",
"      Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/19\">",
"      Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer 1992; 28:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/20\">",
"      Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/21\">",
"      Culine S, Kramar A, Th&eacute;odore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/22\">",
"      Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/23\">",
"      Lewis CR, Foss&agrave; SD, Mead G, et al. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991; 2:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/24\">",
"      Germ&agrave;-Lluch JR, Garcia del Muro X, Tabernero JM, et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 1999; 10:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/25\">",
"      Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003; 21:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/26\">",
"      Anthoney DA, McKean MJ, Roberts JT, et al. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. Br J Cancer 2004; 90:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/27\">",
"      Foss&aring; SD, Paluchowska B, Horwich A, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 2005; 93:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/28\">",
"      Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/29\">",
"      Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993; 23:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/30\">",
"      Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/31\">",
"      Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/32\">",
"      Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/33\">",
"      Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21:4083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/34\">",
"      Bokemeyer C, Kollmannsberger C, Meisner C, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999; 17:3450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/35\">",
"      Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24568/abstract/36\">",
"      Calabr&ograve; F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol 2012; 61:1212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2981 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24568=[""].join("\n");
var outline_f23_63_24568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H547494225\">",
"      DEFINITION OF RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H547494364\">",
"      Seminomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547494371\">",
"      - Good risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547494378\">",
"      - Intermediate risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H547494385\">",
"      Nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547494392\">",
"      - Good risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547494399\">",
"      - Intermediate risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547494406\">",
"      - Poor risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1195404\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Good-risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10825925\">",
"      - Blemoycin, etoposide, and cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10826096\">",
"      - Etoposide and cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Is there a role for carboplatin?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chemotherapy-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intermediate- and poor-risk advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29429295\">",
"      - Chemotherapy-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 2\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/46/42732\" title=\"table 3\">",
"      Risk strat system advancted TGCTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 4\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=related_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19858?source=related_link\">",
"      Treatment protocols for germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_63_24569="Hepatic resection";
var content_f23_63_24569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic resection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Evan S Glazer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24569/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/63/24569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17917389\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic (liver) resection is needed to manage many types of pathology, malignant and benign. Planning a hepatic resection needs to take into account the nature of the lesion and its location within the liver, the patient's anatomy, and the quality and volume of the liver tissue that will remain after resection. Perioperative outcomes for hepatic resection have improved due to better surgical techniques that take advantage of the segmental anatomy of the liver, improved techniques for control of bleeding, and other factors such as improved intensive care. In addition, hepatic resections are increasingly being performed primarily in tertiary centers by specially trained hepatobiliary surgeons who have higher case volumes.",
"   </p>",
"   <p>",
"    Surgical resection of the liver and complications of liver resection will be reviewed here. Specific management of pathologies that indicate the need for liver resection and disease-specific outcomes related to liver resection are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29880?source=see_link\">",
"     \"Surgical techniques for managing hepatic injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124056006\">",
"    <span class=\"h1\">",
"     LIVER ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is divided into two lobar segments (right and left), and is further subdivided into eight (Couinaud) segments based upon its vascular supply or bile duct distribution (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ). The segmental anatomy of the liver is the basis for the various types of anatomic hepatic resections. The surgical anatomy of the liver and types of hepatic resections are discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498479792\">",
"    <span class=\"h2\">",
"     Liver function and regeneration after resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the liver&rsquo;s important functions is the removal of harmful metabolites and other substances, which can damage the liver tissue. The hepatocytes perform a variety of other metabolic functions including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Removing metabolic waste products, hormones, drugs, toxins",
"     </li>",
"     <li>",
"      Producing bile to aid in digestion",
"     </li>",
"     <li>",
"      Processing nutrients absorbed from the digestive tract",
"     </li>",
"     <li>",
"      Storing certain vitamins, minerals, and glycogen",
"     </li>",
"     <li>",
"      Maintenance of normal blood sugar",
"     </li>",
"     <li>",
"      Synthesizing plasma proteins, albumin, clotting factors",
"     </li>",
"     <li>",
"      Producing immune factors and removing bacteria",
"     </li>",
"     <li>",
"      Removing senescent red blood cells from the circulation",
"     </li>",
"     <li>",
"      Excreting bilirubin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The volume of liver needed to maintain these important metabolic functions following liver resection depends upon the quality of the remaining liver tissue. The functional liver reserve (by volume) or post-resection future liver remnant should be greater than 20 percent if there is no evidence of diffuse liver disease (with minimal comorbidities), greater than 30 percent for minimal liver dysfunction such as non-alcohols steatohepatitis (NASH) provided there are minimal other comorbidities, and greater than 40 percent if there is major liver dysfunction compared with healthy individuals or cirrhosis",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    major comorbidities present) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H93290273\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The liver is capable of regeneration, a characteristic that is fundamental to hepatic resection. Although the exact amount of hepatic tissue regenerated will vary from patient to patient, healthy livers can regenerate significant amounts of liver within weeks to months after resection. The mechanisms responsible for this capability are an area of active research [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/5\">",
"     5",
"    </a>",
"    ]. Some patients experience deficient regeneration and functional failure if the liver remnant is too small. (See",
"    <a class=\"local\" href=\"#H93290273\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Preoperative portal vein embolization before large volume hepatic resections can be performed to stimulate liver hyperplasia in the remnant liver [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1124057405\">",
"     'Preoperative portal vein embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93290227\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HEPATIC RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant tumor within the liver (primary or secondary) is the most common indication for hepatic resection. However, benign liver conditions, which can be congenital or acquired, may also require hepatic resection. Although hepatic trauma is most commonly managed conservatively, on occasion, hepatic resection may be required to definitively manage hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93290252\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying conditions of the liver known to predispose to malignancy are generally screened at regular intervals for the development of cancer with imaging studies (ultrasound, computed tomography, magnetic resonance) and serum markers (alpha fetoprotein) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In susceptible patients, a lesion that is clearly not a benign cyst is considered malignant until proven otherwise, and dysplastic nodules are considered pre-malignant lesions and generally treated as malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/8\">",
"     8",
"    </a>",
"    ]. Hepatocellular carcinoma is the most common primary hepatic malignancy, which can occur in the context of inherited (eg, hemochromatosis) or acquired (eg, chronic hepatitis C, alcoholic cirrhosis) pre-existing conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The liver is a common site for metastasis from solid tumors. In selected patients with focal or isolated disease, resection of liver metastases is associated with low rates of major perioperative morbidity (about 3 percent) and mortality (about 4 percent) with good long-term results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Neuroendocrine lesions, primarily from the foregut, are another source of metastases that respond well to liver resection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Surgical treatment of gallbladder cancer involves resection of the gallbladder and involved tissues to obtain a tumor-free margin. However, less than half of patients are candidates for resection at time of diagnosis because of advanced disease. Provided there is no evidence of disease elsewhere, options for hepatic resection in patients with gallbladder cancer include extended cholecystectomy (en block resection gallbladder and a rim of liver), re-resection of portions of segments IVb and V, and less commonly, right hemihepatectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93290259\">",
"    <span class=\"h2\">",
"     Benign disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple cysts, hemangiomas, adenomas, and focal nodular hyperplasia comprise the majority of benign hepatic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/16-19\">",
"       16-19",
"      </a>",
"      ]. Symptomatic lesions causing pain or discomfort can be resected with minimal margins, often laparoscopically [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/20\">",
"       20",
"      </a>",
"      ]. Most asymptomatic lesions are managed conservatively and will not require resection; however, some asymptomatic lesions, such as large or giant hemangiomas, and adenomas larger than 4 to 5 cm, warrant resection when anatomically feasible [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29816?source=see_link\">",
"       \"Hepatic hemangioma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=see_link\">",
"       \"Hepatic adenoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=see_link\">",
"       \"Diagnosis and management of cystic lesions of the liver\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial hepatic abscesses are generally managed with broad-spectrum antibiotics and percutaneous drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Surgical resection may be needed to bring the infection under control. In one study, aggressive, local surgical resection of hepatic resection for pyogenic abscess was beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"       \"Pyogenic liver abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amebic liver abscesses are usually treated effectively with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      without the need for surgical intervention, biopsy, or drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/24\">",
"       24",
"      </a>",
"      ]. However, liver resection may be an option for the few very large abscesses where rupture is a concern, for patients who do not respond to medical treatment, or when the diagnosis is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link&amp;anchor=H2#H2\">",
"       \"Extraintestinal Entamoeba histolytica amebiasis\", section on 'Amebic liver abscess'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93290266\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the management of liver trauma is primarily conservative, liver resection may be needed to control hemorrhage from higher grade (grade IV, V) liver injuries. The grading of liver injuries and approach to the management of liver trauma in adults is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=see_link\">",
"     \"Management of hepatic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29880?source=see_link\">",
"     \"Surgical techniques for managing hepatic injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93290273\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with underlying functional liver disease (eg, cirrhosis, nonalcoholic steatohepatitis), the risk of perioperative morbidity and mortality is high, and patients with severe disease may not tolerate liver resection. Alternative therapies for those with contraindications to hepatic resection may include",
"    <span class=\"nowrap\">",
"     percutaneous/laparoscopic",
"    </span>",
"    ablation, transarterial embolization, and liver transplant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cirrhosis is a significant risk factor for perioperative mortality. In a series of over 100 resections for hepatocellular carcinoma, the presence of cirrhosis (95 percent Child-Pugh A patients) increased operative mortality from 1 to 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/25\">",
"       25",
"      </a>",
"      ]. Mortality of Child-Pugh Class C patients ranges from 30 percent to 100 percent, depending upon the extent of liver resection. We consider cirrhotic patients with Child-Pugh C as unresectable, Child-Pugh B with a future liver remnant &lt;30 percent as absolutely unresectable. Child-Pugh A patients may be relatively unresectable.",
"     </li>",
"     <li>",
"      Nonalcoholic steatohepatitis (NASH) is a continuum of liver injury identified by morphological changes that is highly associated with obesity, diabetes, and inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/26\">",
"       26",
"      </a>",
"      ]. There are few data on the safety of hepatic resection in non-cirrhotic NASH patients, but it may be reasonable to stratify these patients as medium or high risk due to the presence of other comorbidities such as insulin resistance, cardiovascular disease, or morbid obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients with NASH have a higher perioperative morbidity and mortality rate, and the volume of liver remaining after resection (the future liver remnant) should be higher than in patients with normal liver tissue. We offer patients with NASH resection provided the future liver remnant is greater than 30 percent and there are no other major comorbidities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree to which these comorbidities constitute relative versus absolute contraindications to hepatic resection depends upon the ability to properly risk-stratify patients and local resources, such as the availability and proximity of liver transplantation, in the event of fulminant liver failure. Model for end-stage liver disease (MELD) scores do not directly impact decision-making related to liver resection but may be useful in counseling a patient when deciding between liver resection and transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In these cases, perioperative mortality after resection, death from primary disease, and risks associated with transplant need to be taken into account. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124058604\">",
"    <span class=\"h1\">",
"     PREOPERATIVE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain a preoperative imaging study on all patients undergoing elective hepatic resection. When obtaining preoperative imaging prior to hepatic resection, it is important to obtain the highest quality imaging available. At some institutions, this will be computed tomography [CT], and at others, magnetic resonance imaging [MRI]; either is a reasonable choice. The most experienced radiologist available with the chosen modality should provide the interpretation, and the surgeon must be comfortable interpreting the images.",
"   </p>",
"   <p>",
"    Multiphase computed tomography (CT) includes noncontrast, arterial, venous, and portal phases, and includes volumetric analysis of the functional liver remnant. The arterial phase identifies critical arterial anatomy, aberrant vessels (such as replaced arteries), and defines the relationship of intrahepatic tumors to critical vascular or biliary structures. If the portal venous phase is omitted, there is a danger that small, isodense hepatocellular carcinoma lesions could be missed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/30\">",
"     30",
"    </a>",
"    ]. Although CT is more commonly used, MRI may surpass CT in clinical utility as it becomes more time efficient, cost effective and more readily available.",
"   </p>",
"   <p>",
"    Other imaging modalities such as ultrasound, positive emission tomography (PET), and single photon emission computed tomography (SPECT) may be useful adjuncts in management; however, for defining anatomy in planning hepatic resection, poor resolution limits their usefulness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93289159\">",
"    <span class=\"h2\">",
"     Type and extent of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of hepatic resection include wedge resection, segmental resection (sectionectomy, sectorectomy), hepatectomy (right or left), and extended hepatectomy (right or left) (",
"    <a class=\"graphic graphic_figure graphicRef66282 \" href=\"UTD.htm?14/43/15031\">",
"     figure 2",
"    </a>",
"    ). These resections are based upon the segmental anatomy of the liver (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ). The type of hepatic resection chosen depends upon the location of the lesion(s), the ability to provide an adequate liver remnant, and for malignant disease, a tumor-negative margin.",
"   </p>",
"   <p>",
"    Some surgeons prefer anatomic resection according to Couinaud segments (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"UTD.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ) rather than nonanatomic resection because of reports of improved perioperative outcomes and long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, nonanatomic resection may be needed if anatomic resection will result in inadequate residual liver volume to support recovery, such as in the patient with cirrhosis. A disadvantage of nonanatomic resection may be more bleeding; however, inflow occlusion (Pringle maneuver) can be helpful for reducing blood loss.",
"   </p>",
"   <p>",
"    Bilobar metastatic malignant disease is typically found in two variants: small lesions in fewer than four segments and larger lesions diffusely spread throughout the liver. The former can be resected with similar outcomes using using two partial anatomic or nonanatomic hepatic resections, provided sufficient healthy liver remains [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/35\">",
"     35",
"    </a>",
"    ]. Another option is resection of one lesion and radiofrequency ablation of the second [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/36\">",
"     36",
"    </a>",
"    ]. Portal vein embolization can be performed to induce hypertrophy of the parenchyma, allowing bilateral or staged resections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1124057405\">",
"     'Preoperative portal vein embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tumor invasion into the diaphragm may require resection of a portion of the diaphragm. However, the long-term benefit to patients of this extended procedure is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. We currently believe it is reasonable to resect this tumor, particularly if accomplished en-bloc. Mesh repair of the defect has been reported, but the oncologic consequences are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93289181\">",
"    <span class=\"h2\">",
"     Resection margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The margin of resection depends upon the indication for liver resection. Data to guide the tumor margin size is relatively sparse. We suggest a margin of at least 1 cm when resecting malignant tumor. A margin of 2 cm may be even more desirable for aggressive tumor biology, but this is frequently not possible. As an example, for tumor in proximity to major vascular structures, a resection margin of only a few millimeters may be all that can be achieved.",
"   </p>",
"   <p>",
"    For resecting colorectal metastases, some suggest that a negative margin as small as 1 mm (compared with a traditional 1 cm margin) is adequate, but this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It is possible that other types of metastatic lesions could be treated in a similar fashion, but until more evidence is available for other specific types of liver metastases, we prefer at least a 5 mm tumor-free margin, if at all possible.",
"   </p>",
"   <p>",
"    We use a 1 cm margin for hepatocellular carcinoma or cholangiocarcinoma because of lower recurrence rates with this margin and slightly prolonged rates of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/43-47\">",
"     43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The literature is not clear as to the &ldquo;optimal&rdquo; margin in gallbladder cancer, but we believe a 5 mm tumor-free margin is reasonable with a 1 to 2 cm tumor free margin being the goal if re-resection is being undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=see_link&amp;anchor=H99392019#H99392019\">",
"     \"Surgical management of gallbladder cancer\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124057405\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PORTAL VEIN EMBOLIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative portal vein embolization (PVE) is a valuable adjunct to major liver resection, particularly for right-sided tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. PVE can initiate hypertrophy of the anticipated future liver remnant and allow a more extensive resection, or allow for staged, bilateral resections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/5\">",
"     5",
"    </a>",
"    ]. The application of portal vein embolization in selected patients has improved survival and reduced rates of postoperative liver failure following extended hepatic resections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/1,3,52\">",
"     1,3,52",
"    </a>",
"    ]. PVE is most valuable for patients with mild hepatic disease (fatty liver with no metabolic dysfunction) and a marginal future liver remnant (eg, 30 percent before PVE). Patients with poor hepatic function (eg, cirrhosis) or who clearly have a sufficient future liver remnant (eg, &gt;50 percent) do not have favorable",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio for PVE.",
"   </p>",
"   <p>",
"    In considering the need for PVE, the ratio of future liver remnant and total estimated liver volume should be calculated. If the volume of the future liver remnant is less than 20 percent in a patient with a normal liver, or less than 40 percent in a patient with a cirrhotic liver, PVE can be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/53\">",
"     53",
"    </a>",
"    ]. Systemic disease such as diabetes may limit hepatic hypertrophy and the success of the procedure.",
"   </p>",
"   <p>",
"    Two techniques can be used for PVE: transileocolic portal embolization (TIPE) and percutaneous transhepatic portal embolization (PTPE).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TIPE procedure is performed via a minilaparotomy and requires general anesthesia.",
"     </li>",
"     <li>",
"      The percutaneous approach (PTPE), which is more commonly used [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/49\">",
"       49",
"      </a>",
"      ], can be performed in the radiology suite with local anesthesia and conscious sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volumetric assessment of the liver volume with CT imaging should be done before PVE and repeated after PVE before undertaking surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498480683\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least five potential benefits to the use of PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postresection morbidity is diminished, as evidenced by minimal reductions in post-resection liver function [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/55\">",
"       55",
"      </a>",
"      ], fewer pulmonary complications, and decreased length of intensive care unit and inpatient hospitalization.",
"     </li>",
"     <li>",
"      Patients who were initially unresectable because of insufficient remaining normal hepatic parenchyma can undergo resection for potential cure.",
"     </li>",
"     <li>",
"      Subclinical disease or rapid progression may be detected prior to definitive surgery on postembolization imaging studies, thus preventing an unnecessary operation.",
"     </li>",
"     <li>",
"      The volume of remaining liver standardized to patient size (body surface area) predicts mortality after resection in cirrhotics, and the increase in functional liver volume achieved by PVE may decrease mortality of resection in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/48,55,56\">",
"       48,55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of compensatory hypertrophy in response to successful PVE indicates the patient is not suitable for major hepatic resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93289947\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some reports have shown accelerated tumor growth in the liver after PVE. However, these problems with tumor growth are not seen when all of the tumor-bearing areas of the liver are embolized [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/4\">",
"     4",
"    </a>",
"    ]. Other risks associated with PVE are similar to those of any percutaneous intervention such as bleeding, infection, pseudoaneurysm, arteriovenous fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93289684\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient undergoing hepatic resection involves medical risk assessment and a determination of the location of the lesion using imaging studies, expected margins of resection, and the volume of the residual liver remnant. Together, these will determine if resection is feasible, and if so, the extent of the resection. Some patients may benefit from portal vein embolization.",
"   </p>",
"   <p>",
"    Prior to hepatic resection, we have a frank conversation with the patient and their family regarding the benefits of hepatic resection and potential complications, including cardiac, pulmonary, and renal dysfunction, and, for those at risk, possible liver failure. The risk of bile duct injury and bile leak and the potential need for repair, which might require an additional procedure, such as a hepaticojejunostomy or other biliary-enteric anastomosis should also be addressed. (See",
"    <a class=\"local\" href=\"#H93291889\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient should understand that the procedure usually begins with diagnostic laparoscopy and intraoperative ultrasound, and if unresectable hepatic or extrahepatic lesions are found, the procedure will be terminated without hepatic resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93289709\">",
"    <span class=\"h2\">",
"     Medical risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of operative risk prior to liver resection includes establishing the severity of liver disease, and the presence of other medical comorbidities. The majority of hepatic resections are performed under elective circumstances under which there is adequate time for risk assessment and optimization of the patient's medical status. Preoperative medical assessment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to hepatic resection, a complete blood count, serum chemistries and liver function tests, albumin and coagulation studies should be obtained. Patients with severe liver dysfunction may not tolerate the extent of resection that would otherwise be indicated. (See",
"    <a class=\"local\" href=\"#H93290273\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk stratification for hepatic resection depends upon properly identifying those with liver tissue abnormalities. Core liver biopsy should be performed if there is any concern about NASH, chemotherapy-induced steatohepatitis, or liver fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124057442\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is generally regarded as clean surgery, provided there is no underlying infection. Antibiotic prophylaxis for hepatic resection has been evaluated in a single, randomized trial, which suggested that routine prophylaxis prior to hepatic resection is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/57\">",
"     57",
"    </a>",
"    ]. In general, we give preoperative antibiotics directed against skin flora (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). Prophylactic antibiotics should be given within one hour of incision based upon data from other surgeries that involve the liver and biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124057450\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing major liver resection are at moderate to high risk for thromboembolism (",
"    <a class=\"graphic graphic_table graphicRef83739 \" href=\"UTD.htm?22/50/23341\">",
"     table 2",
"    </a>",
"    ), due to the nature of the surgery (major open surgery &gt;45 minutes) and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/59\">",
"     59",
"    </a>",
"    ]. We place intermittent pneumatic compression devices prior to induction and continue their use until the patient is ambulatory. Pharmacologic prophylactic anticoagulation is recommended for moderate and high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H37#H37\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Moderate risk general and abdominal-pelvic surgery patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H38#H38\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk general and abdominal-pelvic surgery patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17917463\">",
"    <span class=\"h1\">",
"     HEPATIC RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is performed in a stepwise fashion starting with laparoscopy and ultrasound imaging to evaluate the potential for complete resection and to define the relevant anatomy. For most resection, cholecystectomy is performed followed by dissection of the porta hepatis to isolate and control the vascular and ductal structures. Thereafter, the liver tissue is divided to the extent that is mandated by the type of liver resection being undertaken, and hemostasis achieved prior to abdominal closure. The general techniques used for hepatic resection and manner in which specific resections are performed are discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17917587\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following discharge, the patient should return to see their surgeon one to two weeks after the surgery to assess wound healing and their recovery progress. The patient should also follow up with their primary physician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical oncologist within a month of discharge regarding long-term treatment plans and options for adjuvant therapy.",
"   </p>",
"   <p>",
"    We advocate surgical follow-up again at three to six months and at 12 months for ongoing evaluation of the surgical incision, the patient&rsquo;s weight, and hepatic function. For patients with malignancy, we continue to follow-up every six months to assess for recurrent disease or new metastatic disease to the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291889\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of complications after hepatic resection is up to 40 percent for patients without cirrhosis, and higher in patients with some degree of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/14,25,60-62\">",
"     14,25,60-62",
"    </a>",
"    ]. However, major complications occur in about 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. These include bile leak, post-hepatectomy coagulopathy, hyperglycemia, pulmonary complications, and liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291896\">",
"    <span class=\"h2\">",
"     Bile leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leak is the most common complication following hepatic resection occurring in less than 10 percent of patients. The majority of bile leaks can be managed with endoscopic decompression and percutaneous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291903\">",
"    <span class=\"h2\">",
"     Coagulopathy and hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of post-hepatectomy coagulopathy is difficult to determine. Factors that contribute to coagulopathy following hepatic surgery include hemodynamic instability, blood loss, preexisting hepatic dysfunction, acute liver injury in the remnant liver tissue, and hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/61,64,66,67\">",
"     61,64,66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We correct any coagulation abnormalities that are identified intraoperatively and postoperatively using early and aggressive component transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291910\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative hyperglycemia is common following major hepatic resection. Uncontrolled hyperglycemia is associated with a higher risk of infection and other postoperative complications. Thus, following major hepatic resection, the majority of patients are placed on an insulin drip to maintain euglycemia (blood glucose between 90 and 120",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    until longer-acting insulin is effective at controlling blood glucose levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291917\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications following open upper abdominal surgery are common because the incision and surgical exposure alter respiratory physiology. Patients undergoing hepatic resection are at increased risk for pleural effusion and pneumonia, which occurred in 40 and 22 percent, respectively, in a review of 555 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/68\">",
"     68",
"    </a>",
"    ]. In this study, independent risk factors for pleural effusion on multivariate analysis included prolonged surgery, surgery of the right lobe of the liver, neoadjuvant chemotherapy, and bilateral subcostal (ie, Chevron) incision. Risk factors for pneumonia included intraoperative blood transfusion, diabetes, and atrial fibrillation. The diagnosis and treatment of pleural effusion and pneumonia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93291924\">",
"    <span class=\"h2\">",
"     Liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most severe complication of hepatic resection is hepatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/61\">",
"     61",
"    </a>",
"    ]. Risk factors for liver failure include underlying liver dysfunction and an insufficient amount of residual liver following resection. Prevention remains the most effective tool for the &ldquo;treatment&rdquo; of hepatic insufficiency. As such, the importance of an adequate future liver remnant cannot be overly stressed. (See",
"    <a class=\"local\" href=\"#H93290273\">",
"     'Contraindications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1498479792\">",
"     'Liver function and regeneration after resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Management of liver failure is primarily supportive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124055866\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety-day mortality following hepatic resection is about 1 to 3 percent at high-volume centers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/61\">",
"     61",
"    </a>",
"    ]. Cirrhosis is a significant risk factor for perioperative mortality following hepatic resection. In a series of over 100 hepatic resections for hepatocellular carcinoma, the presence of cirrhosis (95 percent Child-Pugh A) increased operative mortality from 1 percent to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/25\">",
"     25",
"    </a>",
"    ]. Mortality of Child-Pugh Class C patients varies from 30 percent to 100 percent, depending on the liver operation undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term survival following hepatic resection depends upon the pathology treated, and for malignancies, the ability to achieve a negative margin. As examples, hepatic resection of colorectal metastases is associated with an overall 1, 5, and 10-year survival of 93 percent, 47 percent, and 28 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/69\">",
"     69",
"    </a>",
"    ]. Overall, five-year survival following resection of hepatocellular carcinoma ranges from 60 percent for small, nonfibrotic lesions (T1F0) to 10 percent for large, fibrotic lesions (T3F1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24569/abstract/70\">",
"     70",
"    </a>",
"    ]. The prognosis of these malignancies is discussed in detail elsewhere, as are the outcomes of the various benign pathologies treated with hepatic resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1124063256\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic (liver) resection is used to manage many types of pathology. Malignant tumor within the liver (primary or secondary) is the most common indication for hepatic resection. Benign liver conditions that require hepatic resection are usually symptomatic and can be congenital or acquired. Hepatic trauma is most commonly managed conservatively, but on occasion, will require hepatic resection to definitively manage hemorrhage. (See",
"      <a class=\"local\" href=\"#H93290227\">",
"       'Indications for hepatic resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation of patients undergoing hepatic resection involves medical risk assessment and imaging studies to determine the location of the lesion, potential margins of resection, and volume of the future residual liver remnant. Together, these will determine if resection is feasible, and if so, the type and extent of the resection that will be needed. (See",
"      <a class=\"local\" href=\"#H93289684\">",
"       'Preoperative evaluation and preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with normal liver function, we do",
"      <strong>",
"       not",
"      </strong>",
"      perform hepatic resection if the future liver remnant will be less than 20 percent of the total volume of the liver. For patients with cirrhosis, we do",
"      <strong>",
"       not",
"      </strong>",
"      perform hepatic resection if the liver remnant will be less than 40 percent of the total volume of the liver. For patients with nonalcoholic steatohepatitis (NASH), we do",
"      <strong>",
"       not",
"      </strong>",
"      perform hepatic resection if the liver remnant will be less than 30 percent of the total volume of the liver. (See",
"      <a class=\"local\" href=\"#H93290273\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1498479792\">",
"       'Liver function and regeneration after resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a functional liver remnant that contraindicates hepatic resection (see above), portal vein embolization (PVE) can be performed. PVE stimulates liver hyperplasia in the remnant liver. PVE in patients with certain malignancies has improved survival and reduced rates of postoperative liver failure following extended hepatic resections. (See",
"      <a class=\"local\" href=\"#H1124057405\">",
"       'Preoperative portal vein embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We administer antibiotic prophylaxis one hour prior to incision in patients undergoing hepatic resection. (See",
"      <a class=\"local\" href=\"#H1124057442\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For malignant liver lesions, we use a margin of at least 1 cm rather than a lesser amount, whenever possible. A margin of 2 cm may be even more desirable for aggressive tumor biology, but this is frequently not a possibility. Benign lesions (hemangiomas, adenomas, complex cysts, fibronodular hyperplasia) can be excised by enucleation or resection with limited margins. (See",
"      <a class=\"local\" href=\"#H93289181\">",
"       'Resection margins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At high-volume centers, perioperative mortality following hepatic resection is about 1 to 3 percent and is highest among patients with underlying liver disease. Long-term survival depends upon the specific pathology for which the hepatic resection was performed. Complications (any kind) occur overall in up to 40 percent of patients without cirrhosis, with a higher incidence in patients with some degree of cirrhosis. Major complications include bile leak, coagulopathy and postoperative bleeding, hyperglycemia and liver failure. In patients with no evidence of diffuse liver disease and minimal comorbidities, liver failure is uncommon following limited resections (ie, adequate liver remnant). (See",
"      <a class=\"local\" href=\"#H93291889\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1124055866\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/1\">",
"      Ferrero A, Vigan&ograve; L, Polastri R, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg 2007; 31:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/2\">",
"      Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 2009; 250:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/3\">",
"      van den Esschert JW, de Graaf W, van Lienden KP, et al. Volumetric and functional recovery of the remnant liver after major liver resection with prior portal vein embolization : recovery after PVE and liver resection. J Gastrointest Surg 2009; 13:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/4\">",
"      Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/5\">",
"      Mortensen KE, Revhaug A. Liver regeneration in surgical animal models - a historical perspective and clinical implications. Eur Surg Res 2011; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/6\">",
"      Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/7\">",
"      Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006; 24:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/8\">",
"      Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006; 106:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/9\">",
"      Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/10\">",
"      Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/11\">",
"      Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/12\">",
"      Reddy SK, Barbas AS, Marroquin CE, et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 2007; 204:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/13\">",
"      Simons JP, Ng SC, Hill JS, et al. In-hospital mortality for liver resection for metastases: a simple risk score. J Surg Res 2009; 156:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/14\">",
"      Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/15\">",
"      Liu DM, Kennedy A, Turner D, et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 2009; 32:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/16\">",
"      Charny CK, Jarnagin WR, Schwartz LH, et al. Management of 155 patients with benign liver tumours. Br J Surg 2001; 88:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/17\">",
"      Bonney GK, Gomez D, Al-Mukhtar A, et al. Indication for treatment and long-term outcome of focal nodular hyperplasia. HPB (Oxford) 2007; 9:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/18\">",
"      Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol 2008; 15:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/19\">",
"      Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001; 136:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/20\">",
"      Pulitan&ograve; C, Aldrighetti L. The current role of laparoscopic liver resection for the treatment of liver tumors. Nat Clin Pract Gastroenterol Hepatol 2008; 5:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/21\">",
"      Chen SC, Tsai SJ, Chen CH, et al. Predictors of mortality in patients with pyogenic liver abscess. Neth J Med 2008; 66:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/22\">",
"      Johannsen EC, Sifri CD, Madoff LC. Pyogenic liver abscesses. Infect Dis Clin North Am 2000; 14:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/23\">",
"      Hsieh HF, Chen TW, Yu CY, et al. Aggressive hepatic resection for patients with pyogenic liver abscess and APACHE II score &gt; or =15. Am J Surg 2008; 196:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/24\">",
"      Stanley SL Jr. Amoebiasis. Lancet 2003; 361:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/25\">",
"      Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/26\">",
"      Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/27\">",
"      Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/28\">",
"      Xu Q, Gu L, Wu ZY. Operative treatment for patients with cholelithiasis and liver cirrhosis. Hepatobiliary Pancreat Dis Int 2007; 6:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/29\">",
"      Hayashida N, Shoujima T, Teshima H, et al. Clinical outcome after cardiac operations in patients with cirrhosis. Ann Thorac Surg 2004; 77:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/30\">",
"      Miller WJ, Baron RL, Dodd GD 3rd, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994; 193:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/31\">",
"      Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/32\">",
"      DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000; 4:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/33\">",
"      Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/34\">",
"      Ochiai T, Sonoyama T, Kikuchi S, et al. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma. J Cancer Res Clin Oncol 2007; 133:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/35\">",
"      Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994; 116:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/36\">",
"      Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003; 20:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/37\">",
"      Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/38\">",
"      Lordan JT, Riga A, Worthington TR, Karanjia ND. Early and long-term outcomes of patients undergoing liver resection and diaphragm excision for advanced colorectal liver metastases. Ann R Coll Surg Engl 2009; 91:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/39\">",
"      Lin MC, Wu CC, Chen JT, et al. Surgical results of hepatic resection for hepatocellular carcinoma with gross diaphragmatic invasion. Hepatogastroenterology 2005; 52:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/40\">",
"      Lau WY, Leung KL, Leung TW, et al. Resection of hepatocellular carcinoma with diaphragmatic invasion. Br J Surg 1995; 82:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/41\">",
"      Arnold D, Rummeny EJ, Kirchner T, et al. [Diagnosis and treatment of liver metastases from primary colorectal tumour]. Onkologie 2009; 32 Suppl 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/42\">",
"      Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran&ccedil;aise de Chirurgie. Cancer 1996; 77:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/43\">",
"      Gigot JF, Glineur D, Santiago Azagra J, et al. Laparoscopic liver resection for malignant liver tumors: preliminary results of a multicenter European study. Ann Surg 2002; 236:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/44\">",
"      Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000; 191:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/45\">",
"      Tralh&atilde;o JG, Kayal S, Dagher I, et al. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007; 54:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/46\">",
"      Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993; 40:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/47\">",
"      Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000; 231:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/48\">",
"      Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/49\">",
"      Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999; 29:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/50\">",
"      Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/51\">",
"      Yoo H, Kim JH, Ko GY, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 2011; 18:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/52\">",
"      Mailey B, Truong C, Artinyan A, et al. Surgical resection of primary and metastatic hepatic malignancies following portal vein embolization. J Surg Oncol 2009; 100:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/53\">",
"      Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/54\">",
"      Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/55\">",
"      Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/56\">",
"      Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/57\">",
"      Wu CC, Yeh DC, Lin MC, et al. Prospective randomized trial of systemic antibiotics in patients undergoing liver resection. Br J Surg 1998; 85:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/58\">",
"      Togo S, Tanaka K, Matsuo K, et al. Duration of antimicrobial prophylaxis in patients undergoing hepatectomy: a prospective randomized controlled trial using flomoxef. J Antimicrob Chemother 2007; 59:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/59\">",
"      Bezeaud A, Denninger MH, Dondero F, et al. Hypercoagulability after partial liver resection. Thromb Haemost 2007; 98:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/60\">",
"      Schroeder RA, Marroquin CE, Bute BP, et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/61\">",
"      Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/62\">",
"      Sano T, Shimada K, Sakamoto Y, et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg 2006; 244:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/63\">",
"      Schemmer P, Friess H, Hinz U, et al. Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg 2006; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/64\">",
"      Shimada M, Matsumata T, Akazawa K, et al. Estimation of risk of major complications after hepatic resection. Am J Surg 1994; 167:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/65\">",
"      Erdogan D, Busch OR, van Delden OM, et al. Incidence and management of bile leakage after partial liver resection. Dig Surg 2008; 25:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/66\">",
"      Meijer C, Wiezer MJ, Hack CE, et al. Coagulopathy following major liver resection: the effect of rBPI21 and the role of decreased synthesis of regulating proteins by the liver. Shock 2001; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/67\">",
"      Tanabe G, Sakamoto M, Akazawa K, et al. Intraoperative risk factors associated with hepatic resection. Br J Surg 1995; 82:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/68\">",
"      Nobili C, Marzano E, Oussoultzoglou E, et al. Multivariate analysis of risk factors for pulmonary complications after hepatic resection. Ann Surg 2012; 255:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/69\">",
"      Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24569/abstract/70\">",
"      Ribero D, Abdalla EK, Thomas MB, Vauthey JN. Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2006; 6:567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15094 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24569=[""].join("\n");
var outline_f23_63_24569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1124063256\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17917389\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124056006\">",
"      LIVER ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498479792\">",
"      Liver function and regeneration after resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93290227\">",
"      INDICATIONS FOR HEPATIC RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93290252\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93290259\">",
"      Benign disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93290266\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93290273\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124058604\">",
"      PREOPERATIVE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93289159\">",
"      Type and extent of resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93289181\">",
"      Resection margins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124057405\">",
"      PREOPERATIVE PORTAL VEIN EMBOLIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498480683\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93289947\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93289684\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93289709\">",
"      Medical risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1124057442\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1124057450\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17917463\">",
"      HEPATIC RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17917587\">",
"      POSTOPERATIVE FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93291889\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93291896\">",
"      Bile leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93291903\">",
"      Coagulopathy and hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93291910\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93291917\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93291924\">",
"      Liver failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124055866\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1124063256\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15094|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15031\" title=\"figure 2\">",
"      Types of hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/50/23341\" title=\"table 2\">",
"      Caprini risk assessment model",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8104?source=related_link\">",
"      Diagnosis and management of cystic lesions of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=related_link\">",
"      Hepatic adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29816?source=related_link\">",
"      Hepatic hemangioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=related_link\">",
"      Management of hepatic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=related_link\">",
"      Surgical management of gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29880?source=related_link\">",
"      Surgical techniques for managing hepatic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_63_24570="Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis";
var content_f23_63_24570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24570/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24570/contributors\">",
"     Robert Hostoffer, DO, FACOP, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24570/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/63/24570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/63/24570/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/63/24570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective IgA deficiency (sIgAD) (MIM 137100) may be defined as the isolated deficiency of serum IgA (ie, in the setting of normal serum levels of IgG and IgM) in a patient older than four years of age, in whom other causes of hypogammaglobulinemia have been excluded.",
"   </p>",
"   <p>",
"    The clinical manifestations of sIgAD are variable, ranging from no symptoms to recurrent infections and autoimmune disease. This topic will review the epidemiology, clinical manifestations, diagnosis, and pathophysiology of selective IgA deficiency. The management and prognosis of patients with this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link\">",
"     \"Selective IgA deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL BIOLOGY OF IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA accounts for more than 70 percent of total immunoglobulin in the body, although its concentration in the serum is low [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/1\">",
"     1",
"    </a>",
"    ]. IgA is concentrated in mucosal secretions, including nasal and pulmonary secretions, saliva, tears, breast milk, and secretions of the genitourinary and intestinal tracts. IgA is found in two forms: monomeric serum IgA and dimeric secretory IgA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role in mucosal immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA is believed to be important in mucosal immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Its actions include the coating of microorganisms, to preventing attachment to or penetration of the body surfaces.",
"   </p>",
"   <p>",
"    Monomeric IgA interacts with the phagocytic arm of the immune system. IgA molecules possess a Fab portion that binds foreign antigens (",
"    <a class=\"graphic graphic_figure graphicRef54282 \" href=\"UTD.htm?4/14/4320\">",
"     figure 1",
"    </a>",
"    ). Once bound to an antigen, the Fc portion of IgA binds to the Fc-alpha receptor (CD89) located on the cell surface of neutrophils, eosinophils, and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. IgA binding to the receptor initiates ingestion and destruction of the microorganism by the phagocyte. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dimeric secretory IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dimeric IgA consists of two IgA molecules bound together by a J (joining) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dimeric IgA is secreted from plasma cells that predominantly reside in the connective tissue below the basement membrane of various epithelial tissues (",
"    <a class=\"graphic graphic_figure graphicRef68546 \" href=\"UTD.htm?13/27/13744\">",
"     figure 2",
"    </a>",
"    ). The following steps occur at sites of IgA secretion, such as the gut:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dimeric IgA binds to polymeric immunoglobulin receptors (pIgR) located at the basal aspect of epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/8\">",
"       8",
"      </a>",
"      ]. This same receptor is involved in the transport of pentameric IgM across epithelial surfaces.",
"     </li>",
"     <li>",
"      IgA is subsequently transported to the apical region of epithelial cells by vesicular transport and released into the lumen in combination with a portion of the receptor, known as the secretory component [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/9\">",
"       9",
"      </a>",
"      ]. The entire complex, consisting of two IgA molecules held together at their Fc portions by a J chain and a secretory component, is referred to as secretory IgA. Dimeric IgA molecules bind antigens in the gut and are expelled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the apparent importance of IgA in mucosal immunity, the vast majority of patients with IgA deficiency do not experience more frequent or severe infections. This disconnect between the presumed role of IgA and clinical observations of IgA deficiency is probably explained by the presence of redundant immunologic mechanisms that protect the host from microbial invasion. For example, secretory IgM may perform many of the same functions, and may compensate for lack of IgA in normal neonates and in patients with IgA deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     IgA subclasses",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA has subclasses, IgA1 and IgA2, both of which can exist as monomers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/11\">",
"     11",
"    </a>",
"    ]. Isolated deficiency of IgA1 or IgA2 is rare and has no known clinical significance. As a result, there is no clinical utility to the measurement of IgA subclasses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF IgA DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective IgA deficiency (sIgAD) is the most common immunologic defect in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/12\">",
"     12",
"    </a>",
"    ]. It is considered to be a primary humoral immunodeficiency, although most affected individuals are asymptomatic. Estimates of prevalence are typically obtained through studies of healthy blood donors. Prevalence ranges from 1 in 100 to 1 in 1000 in Caucasian, Black, and Arab populations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/13-20\">",
"     13-20",
"    </a>",
"    ]. The condition is less common in Asian populations, with prevalence rates ranging from 1 in 2600 to 1 in 19,000 in different regions of China and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF IgA DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIgAD is believed to be a heterogeneous disorder that probably arises through several pathogenic mechanisms. The precise molecular defects are unknown. However, most humoral immunodeficiencies arise from either defects in B cells, or defective interactions between B and T cells. A brief review of normal B cell development and antibody production is helpful in understanding the theories of pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Normal B cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial steps in B cell maturation are independent of antigen stimulation and take place in the liver during gestation, and in the bone marrow after birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While in the bone marrow, hematopoietic stem cells normally progress to pre-B cells, which do not demonstrate surface immunoglobulin receptors but contain a cytoplasmic mu heavy chain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/24\">",
"     24",
"    </a>",
"    ]. These mu chains are eventually expressed on the cell surface in association with a pseudolight chain. Failure to progress beyond the pre-B cell stage results in agammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"     \"Agammaglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent steps in B cell maturation occur after B cells interact with exogenous antigen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regulatory T cells; these constitute the antigen-dependent phase and correspond to the generation of the humoral immune response. Further normal B cell development results in the cell surface expression of immunoglobulin M (IgM), followed by surface expression of IgG, IgA, IgD or IgE, together with IgM [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/27\">",
"     27",
"    </a>",
"    ]. The specific immunoglobulin isotype found with IgM determines the antibody isotype the individual cell eventually secretes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     B cells in IgA deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with sIgAD, B cells expressing surface IgA are present, but appear to be developmentally blocked. Theoretically, the defect resides after the surface coexpression of IgM and IgA, although this has not been established with certainty. Based upon animal studies, the failure of B cells to terminally differentiate into plasma cells that secrete IgA may be due to the lack of effects from various cytokines, such as IL-4, IL-6, IL-7, or IL-10, although other mechanisms have also been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/28-33\">",
"     28-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evidence for a genetic predisposition for IgA deficiency is provided by the observations of familial clustering, inheritance patterns, and associations with known genetic loci.",
"   </p>",
"   <p>",
"    The exact pattern of inheritance of IgA deficiency remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/34\">",
"     34",
"    </a>",
"    ]. The most significant risk factor for having IgA deficiency is a family history of either IgA deficiency or the more profound defect in antibody function, common variable immunodeficiency (CVID). First degree relatives of affected individuals are 50 times more likely to be affected themselves, compared with unaffected people. Affected mothers are more likely than affected fathers to transmit the disorder to their offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first genetic defect to be identified in this disorder was a mutation in the tumor necrosis factor receptor family member \"transmembrane activator and calcium-modulator and cyclophilin ligand interactor\" (TACI), which mediates isotype switching in B cells. B cells in these patients expressed TACI, but did not produce IgG and IgA in response to the TACI ligand, suggesting impaired isotype switching [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. TACI mutations have been identified in a small subset of patients with sIgAD, as well as in some patients with CVID. However, it is not clear that these mutations are the causative defect in these disorders, and there are probably additional defects that have not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting findings concerning the presence or absence of large chromosomal abnormalities. Some studies have reported abnormalities involving chromosomes 16 and 18, while other studies have not found consistent abnormalities within IgA deficient families [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/34,40-47\">",
"     34,40-47",
"    </a>",
"    ]. Long or short-arm deletion and ring formation have been described in some patients who are also mentally retarded and exhibit additional dysmorphic features [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/44\">",
"     44",
"    </a>",
"    ]. These findings are probably not relevant to asymptomatic IgA deficient patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Major histocompatibility complex loci associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association has also been suggested between sIgAD and the major histocompatibility complex (MHC):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strong correlations between MHC I, particularly HLA-B8, and IgA deficiency have been reported, although this may be due to the concurrent presence of diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/48-51\">",
"       48-51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A lack of diversity of the MHC II or an amino acid substitution at position 57 of the HLA-DQ beta chain may be associated with a susceptibility for IgA deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Either the telomeric region of the major histocompatibility complex II or the centromeric region of class III may be the location for a susceptibility area for IgA deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/47\">",
"       47",
"      </a>",
"      ]. Others have implicated a susceptibility locus in a region of MHC III that encodes for cytokines needed for immunoglobulin production [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/51\">",
"       51",
"      </a>",
"      ]. These same class III loci may be also associated with other more severe forms of immunodeficiency, such as CVID [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Associated immune deficiencies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The haplotype, MSH5 85F-DRB1*0102 at the telomeric end of HLA class II or in class I or II seems to suggest a susceptibility area for IgAD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2767195\">",
"    <span class=\"h3\">",
"     Non-HLA associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In other studies, IgAD has been associated with variants within the Interferon-induced helicase C domain-containing protein 1 gene (IFIH1). In previous studies this gene has been associated with type 1 diabetes and systemic lupus erythematosus further linking IgAD and autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/54\">",
"     54",
"    </a>",
"    ]. Additionally, a suggestive association has been found with IgAD and variants within the C-type lectin domain family 16 gene (CLEC16A), a known autoimmune locus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Associated immune deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, mutations in TACI have been identified both in patients who have common variable immunodeficiency (CVID) and in those with sIgAD, although these account for a small subset within each disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Some cases of sIgAD may progress to CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In addition, families have been described in which affected individuals progress from a normal immunologic state to IgA deficiency with and without IgG subclass deficiency or CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/34,40,57\">",
"     34,40,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgA deficiency is also associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG2 subclass deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H7#H7\">",
"       \"IgG subclass deficiency\", section on 'IgG2 deficiency'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Selective polysaccharide nonresponse (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ataxia telangiectasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      DiGeorge syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Relationship to autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome wide association studies revealed an association between sIgAD and genetic variants in the gene for IFIH1 and CLEC16A [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/54\">",
"     54",
"    </a>",
"    ]. Mutations in these loci are also associated with autoimmune disorders. These findings tantalizingly draw a loose connection between IgAD and an autoimmune diathesis, although further studies are necessary to show causality.",
"   </p>",
"   <p>",
"    At first glance, it appears paradoxical that an autoimmune disorder could develop in the individual with a humoral immunodeficiency disease, since this would require the emergence of self-reactive antibodies in a host with defective antibody production. Theories about the relationship between autoimmunity and IgA deficiency include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmunity is seen in several types of humoral immunodeficiencies, including selective IgA deficiency and CVID. The immune system is normally prevented from damaging self tissues by the elimination (or negative selection) of cells that strongly react against self antigens. These mechanisms are believed to be compromised in some humoral immunodeficiencies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An alternative theory is that individuals with IgA deficiency have underlying genetic factors that independently predispose to autoimmunity, without there being a direct causal relationship between the IgA deficiency and autoimmune disease. The observation that the prevalence of autoimmune disorders is increased among first degree relatives of patients with IgA deficiency supports this theory [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third theory posits that the compromised mucosal barrier in sIgAD allows for abnormal passage of food antigens through the gut wall. In some patients, this may lead to the formation of autoreactive antibodies and autoimmune disease due to molecular mimicry between large food proteins, such as milk, and host antigens. One study showed the presence of antibodies against milk in patients with IgA deficiency correlated with an increased frequency of serum autoantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinically, sIgAD is associated with the presence of autoantibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    various autoimmune diseases, as described below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Autoimmunity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS IN SYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority (85 to 90 percent) of patients with sIgAD are asymptomatic. The remaining 10 to 15 percent of IgA deficient individuals present with one or more of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent sinopulmonary infections",
"     </li>",
"     <li>",
"      Autoimmune disorders",
"     </li>",
"     <li>",
"      Gastrointestinal infections and other intestinal disorders",
"     </li>",
"     <li>",
"      Anaphylactic transfusion reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum levels of IgA in deficient patients do not necessarily correlate with the occurrence or severity of associated disorders, and the pathophysiologic relationship between the deficiency of IgA and the disorders listed above has not been clearly delineated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathophysiology of IgA deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Food allergies and respiratory allergies (ie, allergic rhinitis and allergic asthma) are also prominent in patients with IgA deficiency, although the true prevalence is not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/60\">",
"     60",
"    </a>",
"    ]. As with other immune disorders, lymphomas and gastrointestinal malignancies have been reported, but it has not been established that patients with sIgAD are at increased risk for neoplastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recurrent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with sIgAD suffer from recurrent infections, most often affecting the sinopulmonary tract. Gastrointestinal infections are seen to a lesser degree. Sinopulmonary infections may be more common than gastrointestinal infections in sIgAD because secreted IgM, which may partially compensate for the deficiency of IgA, is more prominent in the gut than the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sinopulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with sIgAD may experience recurrent otitis media, sinusitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumonia. Adults with sIgAD may also suffer from recurrent sinusitis and pulmonary infections, although otitis media is less common. Encapsulated bacteria (eg, Streptococcus pneumoniae, Haemophilus influenzae) are usually responsible. There have been several reports of patients presenting with end organ damage, such as bronchiectasis, due to chronic and recurrent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated IgA deficiency with recurrent infection may also occur in patients who eventually progress to common variable immunodeficiency (CVID) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/55,64-67\">",
"     55,64-67",
"    </a>",
"    ]. The propensity to progress to CVID may be stronger in familial and MHC-associated IgA deficiency or in patients with 18q deletion syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of common variable immunodeficiency\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some IgA deficient patients suffer from gastrointestinal infections due to Giardia lamblia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with IgA deficiency appear to have adequate defenses against other types of gastrointestinal infections. As an example, patients were shown to clear rotaviral infections normally and generate higher levels of total IgG and IgG1 subclass antibodies, compared to normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients followed in immunology clinics, approximately 20 to 30 percent of patients with sIgAD develop autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Autoantibodies, without overt clinical disease, are present in many patients with sIgAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/74,76-79\">",
"     74,76-79",
"    </a>",
"    ]. In one series comparing 60 IgAD patients with a normal control population, 90 percent had detectable autoantibodies, and 40 percent had six or more autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/76\">",
"     76",
"    </a>",
"    ]. Subjects were evaluated for 21 different autoantibodies, and reactivity to the following antigens was identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sulfatide (32 percent of patients)",
"     </li>",
"     <li>",
"      Jo-1 (28 percent)",
"     </li>",
"     <li>",
"      Cardiolipin (21 percent)",
"     </li>",
"     <li>",
"      Phosphatidylserine (20 percent)",
"     </li>",
"     <li>",
"      Asialo-GM1 (21 percent)",
"     </li>",
"     <li>",
"      Sm (15 percent)",
"     </li>",
"     <li>",
"      Sulfoglucuronyl paragloboside (11 percent)",
"     </li>",
"     <li>",
"      Collagen type I (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study of children with sIgAD found an increased prevalence of autoantibodies and no correlation with symptoms of autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False positive pregnancy tests have been reported in IgA deficient women, a phenomenon that has been attributed to the presence of heterophile antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/81\">",
"     81",
"    </a>",
"    ]. Heterophile antibodies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with sIgAD can also develop overt autoimmune disease. The most commonly reported disorders are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/82-88\">",
"       82-88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Juvenile or adult-onset rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also case reports of patients with Hashimoto's thyroiditis, pernicious anemia, myasthenia gravis, vitiligo, dermatomyositis, Sj&ouml;gren&rsquo;s syndrome, hemolytic anemia, idiopathic thrombocytopenia, and various glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/91-102\">",
"     91-102",
"    </a>",
"    ]. An increased incidence of IgA deficiency may also be found in type I, but not type II, diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders (non-infectious)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease and inflammatory bowel disease occur with increased prevalence in patients with sIgAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening programs have detected celiac disease in up to 8 percent of patients with sIgAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/106\">",
"     106",
"    </a>",
"    ], and 1 to 2 percent of all patients with celiac disease have sIgAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/107\">",
"     107",
"    </a>",
"    ]. Testing strategies are discussed below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Patients with symptoms of celiac disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, are associated with selective IgA deficiency, although the pathophysiologic relationship is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/108-111\">",
"     108-111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nodular lymphoid hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular lymphoid hyperplasia, also known as follicular lymphoid hyperplasia, is a benign finding in the small intestine that is associated with selective IgA deficiency and common variable immunodeficiency, and gastrointestinal lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/112-115\">",
"     112-115",
"    </a>",
"    ]. It is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Predisposing conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anaphylactic reactions to blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are IgA deficient may form antibodies directed against IgA. These antibodies are usually found only in those IgA deficient patients with undetectable serum levels of IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. In theory, anti-IgA antibodies could cause infusion reactions to blood products containing small amounts of IgA in plasma (ie, whole blood, red blood cells, platelets, fresh frozen plasma, cryoprecipitate, granulocytes) or intravenous gammaglobulin (IVIg) preparations containing IgA. Reactions to these products have been described in patients with IgA deficiency, as well as in those with CVID, and can be clinically indistinguishable from anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/116,118-127\">",
"     116,118-127",
"    </a>",
"    ]. However, reactions associated with the presence of anti-IgA antibodies are just one of several causes of",
"    <span class=\"nowrap\">",
"     transfusion/infusion-related",
"    </span>",
"    anaphylaxis, and this etiology is believed to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/117,128,129\">",
"     117,128,129",
"    </a>",
"    ]. The management of IgA deficient patients with reactions to blood products is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link\">",
"     \"Selective IgA deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgG anti-IgA antibodies have been identified in up to 40 percent of sIgAD patients in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/116,118-126\">",
"     116,118-126",
"    </a>",
"    ]. In contrast, IgE anti-IgA was demonstrated in only one individual in a series of 46 IgA deficient patients, and this individual had life-threatening anaphylaxis in response to IVIg [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/120\">",
"     120",
"    </a>",
"    ]. However, most patients with IgA deficiency and anaphylaxis to blood products do not have anti-IgA antibodies (either IgG or IgE), so other causes of reactions to blood products must be considered as well. Testing for the presence of these antibodies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link\">",
"     \"Selective IgA deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for IgA deficiency should be considered in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A child with recurrent otitis media, sinusitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumonia. The evaluation of serum immunoglobulins in children is best undertaken after the age of six months, since maternal immunoglobulins (particularly IgG) are present until this age. For this reason, children with antibody defects do not generally present with recurrent infections until this age, when maternal antibodies have been cleared and the child's underlying deficiency is unmasked.",
"     </li>",
"     <li>",
"      An adult with",
"      <span class=\"nowrap\">",
"       recurrent/chronic",
"      </span>",
"      sinusitis or pulmonary infections",
"     </li>",
"     <li>",
"      A patient of any age with one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Celiac disease",
"     </li>",
"     <li>",
"      Gastrointestinal infection with Giardia lamblia",
"     </li>",
"     <li>",
"      Unexplained and recurrent autoimmune phenomena",
"     </li>",
"     <li>",
"      A family history of IgA deficiency or common variable immunodeficiency (CVID)",
"     </li>",
"     <li>",
"      A past anaphylactic reaction to blood products",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initial laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation should include the measurement of serum concentrations of IgA, IgG, and IgM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA deficiency is diagnosed when a selective deficiency of serum IgA is identified in a patient older than four years of age, in whom other causes of hypogammaglobulinemia have been excluded. In children younger than four years, the diagnosis should be considered preliminary and the child monitored over time to see if IgA levels normalize. Observations about the natural history of selective IgA deficiency are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link&amp;anchor=H13#H13\">",
"     \"Selective IgA deficiency: Management and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two severities of selective IgA deficiency have been distinguished, which correlate with the certainty of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/130\">",
"     130",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe",
"      <span class=\"nowrap\">",
"       deficiency/definitive",
"      </span>",
"      diagnosis &mdash; Patient greater than four years of age with a serum IgA concentration of less than 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (the lower limit of detection for most assays) and normal serum levels of IgG and IgM. Other causes of hypogammaglobulinemia must be excluded.",
"     </li>",
"     <li>",
"      Partial",
"      <span class=\"nowrap\">",
"       deficiency/probable",
"      </span>",
"      diagnosis &mdash; Patient greater than four years of age with a serum IgA concentration higher than 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      but below the lower limit of normal (defined as 2 standard deviations below the age-adjusted mean value). Serum levels of IgG and IgM must be normal and other causes of hypogammaglobulinemia must be excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The measurement of IgA in specific bodily fluids is considered a research tool and is not recommended, since IgA levels in secretions are highly variable. Patients with measurable serum IgA levels have sufficient secretory IgA, and patients with low serum IgA levels (&lt;7",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    can be assumed to have little or no secretory IgA. There is also no need to measure IgA isotypes (IgA1 and IgA2).",
"   </p>",
"   <p>",
"    Functional testing of the patient's humoral immune response using vaccine challenge is not part of the diagnostic criteria for selective IgA deficiency. However, this evaluation is indicated in a patient with recurrent sinopulmonary infections, as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation depends upon the patient's clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Patients with recurrent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to serum levels of IgA, IgG, and IgM, a complete blood count with differential and total hemolytic complement (THC or CH50) assay should be obtained to screen for other immunologic causes of recurrent infections. If the serum IgG level is normal, then IgG subclasses should be measured, as IgG2 subclass deficiency may coexist with IgA deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with selective IgA deficiency may have normal or impaired responses to protein and polysaccharide antigens, although antibody function is not part of the diagnostic criteria. Despite this, assessment of vaccine responses is clinically useful because, if it is impaired, then the cause of the patient's recurrent infections has been identified, and immunoglobulin replacement therapy is indicated. In addition, patients with impaired antibody function should be monitored for evolution to CVID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link\">",
"     \"Selective IgA deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Patients with symptoms of celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for celiac disease is indicated in patients with suggestive symptoms. IgG-antigliadin antibodies or an IgG test for tissue transglutaminase are preferable to IgA-based assays, as the latter may be falsely negative in a patient with sIgAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of celiac disease\", section on 'Suggestive clinical features but negative serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of sIgAD includes other primary immunodeficiencies and secondary IgA deficiency due to medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other primary immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following alternative diagnoses should be excluded in patients with isolated deficiency of serum IgA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient hypogammaglobulinemia of infancy &nbsp;Transient hypogammaglobulinemia of infancy (THI) may be defined as a prolongation of the &ldquo;physiologic&rdquo; hypogammaglobulinemia of infancy, which is normally observed during the first three to six months of life. Vaccine responses are normal in children with THI. The diagnostic criteria for THI vary somewhat worldwide. Most definitions require that IgG be reduced, with or without reductions in other immunoglobulin classes, but some criteria accept an isolated low IgA level as sufficient for the diagnosis. Because of the changing nature of immunoglobulin levels in young children, THI is an appropriate diagnosis for children under four years of age with low immunoglobulin levels, whereas the diagnosis of selective IgA deficiency is best deferred until the child is older.",
"     </li>",
"     <li>",
"      Evolving CVID &nbsp;Some patients with selective IgA deficiency develop common variable immunodeficiency (CVID) over time. Patients who continue to suffer from repeated infections and develop conditions associated with CVID, such as autoimmune hemolytic anemia or thrombocytopenia, should have IgG levels and vaccine responses assessed periodically. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgA deficiency may be detected in a patient with another more severe immunodeficiency, including the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Disorders of antibody function, such as polysaccharide nonresponse (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IgG subclass deficiency (particularly IgG2 deficiency) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ataxia telangiectasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients with these other disorders would not be considered to have selective IgA deficiency, and their evaluation and management would be dictated by the other disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Drug-induced immunoglobulin disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications can cause low levels of IgA, usually in combination with reductions in serum levels of other immunoglobulin classes. Most of these are reversible with discontinuation of the responsible medication, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A has been reported to cause permanent IgA deficiency even after the drug has been stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of drugs that may cause reversible reductions in serum IgA levels include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticonvulsants, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/133-135\">",
"       133-135",
"      </a>",
"      ], valproic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/136\">",
"       136",
"      </a>",
"      ], carbamazepine [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/137\">",
"       137",
"      </a>",
"      ], and zonisamide [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/138\">",
"       138",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      D-penicillamine [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/139-141\">",
"       139-141",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aurothioglucose [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/142\">",
"       142",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       Captopril",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/143,144\">",
"       143,144",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/145\">",
"       145",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fenclofenac [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/146\">",
"       146",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gold [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/147\">",
"       147",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thyroxine [",
"      <a class=\"abstract\" href=\"UTD.htm?23/63/24570/abstract/148\">",
"       148",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective IgA deficiency (MIM 137100) may be defined as the selective deficiency of serum IgA (ie, serum levels of IgG and IgM are normal) in a patient older than four years of age, in whom other causes of hypogammaglobulinemia have been excluded. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgA is concentrated in mucosal secretions and is believed to be important in the immune functioning of the mucosal barrier. However, the vast majority of patients with IgA deficiency do not suffer from increased infections, an observation that has not yet been fully explained. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal biology of IgA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgA deficiency is considered a humoral immunodeficiency, although the majority of patients are asymptomatic. It is the most common immunodeficiency in humans. The pathophysiology is unknown. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology of IgA deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology of IgA deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Only a minority of IgA deficient individuals are symptomatic. These patients may develop recurrent sinopulmonary infections, autoimmune antibodies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disorders, gastrointestinal disorders, and rare anaphylactic reactions to blood products. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations in symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation begins with measurement of serum levels of IgA, IgG, and IgM. Serum levels of IgG and IgM levels must be normal to consider the diagnosis of selective IgA deficiency. Further evaluation depends upon the patient's clinical presentation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two severities of IgA deficiency are distinguished: A serum IgA level &lt;7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is considered severe deficiency. Partial deficiency refers to a level above 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      but below the lower limit of age-adjusted normal. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective IgA deficiency is a diagnosis of exclusion. Other disorders which must be considered include several other immune disorders and secondary IgA deficiency due to medications. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/1\">",
"      Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008; 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/2\">",
"      Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol 2006; 208:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/3\">",
"      Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 2003; 3:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/4\">",
"      Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity 2008; 28:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/5\">",
"      Hostoffer RW, Krukovets I, Berger M. Increased Fc alpha R expression and IgA-mediated function on neutrophils induced by chemoattractants. J Immunol 1993; 150:4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/6\">",
"      Monteiro RC, Hostoffer RW, Cooper MD, et al. Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 1993; 92:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/7\">",
"      Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol 2000; 52:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/8\">",
"      Mostov K, Su T, ter Beest M. Polarized epithelial membrane traffic: conservation and plasticity. Nat Cell Biol 2003; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/9\">",
"      Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol 1994; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/10\">",
"      Brandtzaeg P, Nilssen DE, Rognum TO, Thrane PS. Ontogeny of the mucosal immune system and IgA deficiency. Gastroenterol Clin North Am 1991; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/11\">",
"      Kerr MA. The structure and function of human IgA. Biochem J 1990; 271:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/12\">",
"      Stiehm ER. The four most common pediatric immunodeficiencies. J Immunotoxicol 2008; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/13\">",
"      al-Attas RA, Rahi AH. Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. J Clin Immunol 1998; 18:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/14\">",
"      Pereira LF, Sapi&ntilde;a AM, Arroyo J, et al. Prevalence of selective IgA deficiency in Spain: more than we thought. Blood 1997; 90:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/15\">",
"      Ezeoke AC. Selective IgA deficiency (SIgAD) in Eastern Nigeria. Afr J Med Med Sci 1988; 17:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/16\">",
"      Litzman J, Sevc&iacute;kov&aacute; I, Stikarovsk&aacute; D, et al. IgA deficiency in Czech healthy individuals and selected patient groups. Int Arch Allergy Immunol 2000; 123:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/17\">",
"      Gudmundsson S, Jensson O. Frequency of IgA deficiency in blood donors and Rh negative women in Iceland. Acta Pathol Microbiol Scand C 1977; 85:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/18\">",
"      Saghafi S, Pourpak Z, Aghamohammadi A, et al. Selective immunoglobulin A deficiency in Iranian blood donors: prevalence, laboratory and clinical findings. Iran J Allergy Asthma Immunol 2008; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/19\">",
"      Holt PD, Tandy NP, Anstee DJ. Screening of blood donors for IgA deficiency: a study of the donor population of south-west England. J Clin Pathol 1977; 30:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/20\">",
"      Carneiro-Sampaio MM, Carbonare SB, Rozentraub RB, et al. Frequency of selective IgA deficiency among Brazilian blood donors and healthy pregnant women. Allergol Immunopathol (Madr) 1989; 17:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/21\">",
"      Feng L. [Epidemiological study of selective IgA deficiency among 6 nationalities in China]. Zhonghua Yi Xue Za Zhi 1992; 72:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/22\">",
"      Kanoh T, Mizumoto T, Yasuda N, et al. Selective IgA deficiency in Japanese blood donors: frequency and statistical analysis. Vox Sang 1986; 50:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/23\">",
"      Feng ML, Zhao YL, Shen T, et al. Prevalence of immunoglobulin A deficiency in Chinese blood donors and evaluation of anaphylactic transfusion reaction risk. Transfus Med 2011; 21:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/24\">",
"      Huston DP, Kavanaugh AF, Rohane PW, Huston MM. Immunoglobulin deficiency syndromes and therapy. J Allergy Clin Immunol 1991; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/25\">",
"      Pearl ER, Vogler LB, Okos AJ, et al. B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol 1978; 120:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/26\">",
"      Cooper MD, Lawton AR. Circulating B-cells in patients with immunodeficiency. Am J Pathol 1972; 69:513.",
"     </a>",
"    </li>",
"    <li>",
"     Lawton AR. B cell development. In: Fetal and neonatal physiology, Polin RA, Fox WW (Eds), WB Saunders, Philadelphia 1992. p.1432.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/28\">",
"      Husain Z, Holodick N, Day C, et al. Increased apoptosis of CD20+ IgA + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. J Clin Immunol 2006; 26:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/29\">",
"      Ramsay AJ, Husband AJ, Ramshaw IA, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/30\">",
"      Okahashi N, Yamamoto M, Vancott JL, et al. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun 1996; 64:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/31\">",
"      Snapper CM, Zelazowski P, Rosas FR, et al. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 1996; 156:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/32\">",
"      Bri&egrave;re F, Chevet D, Bridon JM, et al. [B lymphocytes of patients with complete IgA deficiency secrete IgA in response to interleukin 10]. Nephrologie 1996; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/33\">",
"      Kowalczyk D, Mytar B, Zembala M. Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency. J Allergy Clin Immunol 1997; 100:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/34\">",
"      Koistinen J. Familial clustering of selective IgA deficiency. Vox Sang 1976; 30:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/35\">",
"      Vorechovsk&yacute; I, Webster AD, Plebani A, Hammarstr&ouml;m L. Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet 1999; 64:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/36\">",
"      Vorechovsk&yacute; I, Zetterquist H, Paganelli R, et al. Family and linkage study of selective IgA deficiency and common variable immunodeficiency. Clin Immunol Immunopathol 1995; 77:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/37\">",
"      Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/38\">",
"      Rachid R, Castigli E, Geha RS, Bonilla FA. TACI mutation in common variable immunodeficiency and IgA deficiency. Curr Allergy Asthma Rep 2006; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/39\">",
"      Pan-Hammarstr&ouml;m Q, Salzer U, Du L, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet 2007; 39:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/40\">",
"      Vassallo CL, Zawadzki ZA, Simons JR. Recurrent respiratory infections in a family with immunoglobulin A deficiency. Am Rev Respir Dis 1970; 101:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/41\">",
"      Lewkonia RM, Gairdner D, Doe WF. IgA deficiency in one of identical twins. Br Med J 1976; 1:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/42\">",
"      Gilgenkrantz S, Charles JM, Cabrol C, et al. [Deletion of the short arm of chromosome 18 due to t(22-;18p+) translocation with IgA deficiency. Cytogenetic study with autoradiography and fluorescence]. Ann Genet 1972; 15:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/43\">",
"      Murken JD, Salzer G, Kunze D. [Ring-chromosome 18 and IgA deficiency in a 6-year-old girl (46,XX,18r)]. Z Kinderheilkd 1970; 109:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/44\">",
"      Ogata K, Iinuma K, Kammura K, et al. A case report of a presumptive +i(18p) associated with serum IgA deficiency. Clin Genet 1977; 11:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/45\">",
"      Sch&auml;ffer AA, Pfannstiel J, Webster AD, et al. Analysis of families with common variable immunodeficiency (CVID) and IgA deficiency suggests linkage of CVID to chromosome 16q. Hum Genet 2006; 118:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/46\">",
"      Herrmann RP, Chipper L, Bell S. Chromosomal studies in healthy blood donors with IgA deficiency. Clin Genet 1982; 22:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/47\">",
"      Vorechovsk&yacute; I, Cullen M, Carrington M, et al. Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000; 164:4408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/48\">",
"      Lakhanpal S, O'Duffy JD, Homburger HA, Moore SB. Evidence for linkage of IgA deficiency with the major histocompatibility complex. Mayo Clin Proc 1988; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/49\">",
"      Heikkil&auml; M, Koistinen J, Lohman M, Koskimies S. Increased frequency of HLA-A1 and -B8 in association with total lack, but not with deficiency of serum IgA. Tissue Antigens 1984; 23:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/50\">",
"      De La Concha EG, Fernandez-Arquero M, Martinez A, et al. HLA class II homozygosity confers susceptibility to common variable immunodeficiency (CVID). Clin Exp Immunol 1999; 116:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/51\">",
"      Schroeder HW Jr, Zhu ZB, March RE, et al. Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med 1998; 4:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/52\">",
"      Olerup O, Smith CI, Hammarstr&ouml;m L. Different amino acids at position 57 of the HLA-DQ beta chain associated with susceptibility and resistance to IgA deficiency. Nature 1990; 347:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/53\">",
"      Pozo ND, Medrano LM, C&eacute;nit MC, et al. MSH5 is not a genetic predisposing factor for immunoglobulin A deficiency but marks the HLA-DRB1*0102 subgroup carrying susceptibility. Hum Immunol 2010; 71:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/54\">",
"      Ferreira RC, Pan-Hammarstr&ouml;m Q, Graham RR, et al. Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat Genet 2010; 42:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/55\">",
"      Espa&ntilde;ol T, Catala M, Hernandez M, et al. Development of a common variable immunodeficiency in IgA-deficient patients. Clin Immunol Immunopathol 1996; 80:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/56\">",
"      Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol 2008; 147:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/57\">",
"      Johnson ML, Keeton LG, Zhu ZB, et al. Age-related changes in serum immunoglobulins in patients with familial IgA deficiency and common variable immunodeficiency (CVID). Clin Exp Immunol 1997; 108:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/58\">",
"      Jorgensen GH, Thorsteinsdottir I, Gudmundsson S, et al. Familial aggregation of IgAD and autoimmunity. Clin Immunol 2009; 131:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/59\">",
"      Cunningham-Rundles C, Brandeis WE, Pudifin DJ, et al. Autoimmunity in selective IgA deficiency: relationship to anti-bovine protein antibodies, circulating immune complexes and clinical disease. Clin Exp Immunol 1981; 45:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/60\">",
"      Janzi M, Kull I, Sj&ouml;berg R, et al. Selective IgA deficiency in early life: association to infections and allergic diseases during childhood. Clin Immunol 2009; 133:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/61\">",
"      Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/62\">",
"      Chipps BE, Talamo RC, Winkelstein JA. IgA deficiency, recurrent pneumonias, and bronchiectasis. Chest 1978; 73:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/63\">",
"      Gomez-Carrasco JA, Barrera-G&oacute;mez MJ, Garc&iacute;a-Mouri&ntilde;o V, et al. Selective and partial IgA deficiency in an adolescent male with bronchiectasis. Allergol Immunopathol (Madr) 1994; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/64\">",
"      Gutierrez MG, Kirkpatrick CH. Progressive immunodeficiency in a patient with IgA deficiency. Ann Allergy Asthma Immunol 1997; 79:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/65\">",
"      Slyper AH, Pietryga D. Conversion of selective IgA deficiency to common variable immunodeficiency in an adolescent female with 18q deletion syndrome. Eur J Pediatr 1997; 156:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/66\">",
"      Litzman J, Burianova M, Thon V, Lokaj J. Progression of selective IgA deficiency to common variable immunodeficiency in a 16 year old boy. Allergol Immunopathol (Madr) 1996; 24:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/67\">",
"      Hostoffer RW, Bay CA, Wagner K, et al. Kabuki make-up syndrome associated with an acquired hypogammaglobulinemia and anti-IgA antibodies. Clin Pediatr (Phila) 1996; 35:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/68\">",
"      Wilson MG, Towner JW, Forsman I, Siris E. Syndromes associated with deletion of the long arm of chromosome 18[del(18q)]. Am J Med Genet 1979; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/69\">",
"      Eren M, Saltik-Temizel IN, Y&uuml;ce A, et al. Duodenal appearance of giardiasis in a child with selective immunoglobulin A deficiency. Pediatr Int 2007; 49:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/70\">",
"      Carretero Gomez J, Vera Tom&eacute; A, Ar&eacute;valo Lorido JC, Mu&ntilde;oz Sanz A. [Follicular lymphoid hyperplasia, IgA deficiency and coinfecction of Giardia lamblia and Epstein-Barr virus]. Gastroenterol Hepatol 2003; 26:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/71\">",
"      Gato Morais R, B&aacute;&ntilde;ez S&aacute;nchez F, Pascual Garc&iacute;a J, et al. [Reactive arthritis due to Giardia lamblia in a patient with IgA deficiency]. An Med Interna 1998; 15:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/72\">",
"      Langford TD, Housley MP, Boes M, et al. Central importance of immunoglobulin A in host defense against Giardia spp. Infect Immun 2002; 70:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/73\">",
"      Istrate C, Hinkula J, Hammarstr&ouml;m L, Svensson L. Individuals with selective IgA deficiency resolve rotavirus disease and develop higher antibody titers (IgG, IgG1) than IgA competent individuals. J Med Virol 2008; 80:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/74\">",
"      Edwards E, Razvi S, Cunningham-Rundles C. IgA deficiency: clinical correlates and responses to pneumococcal vaccine. Clin Immunol 2004; 111:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/75\">",
"      Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol 2009; 29:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/76\">",
"      Barka N, Shen GQ, Shoenfeld Y, et al. Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A deficiency. Clin Diagn Lab Immunol 1995; 2:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/77\">",
"      Ammann AJ, Hong R. Selective IgA deficiency and autoimmunity. Clin Exp Immunol 1970; 7:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/78\">",
"      Ablin RJ. Anti-tissue IgG antibodies and deficiency of IgA. Vox Sang 1972; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/79\">",
"      Wells JV, Michaeli D, Fudenberg HH. Antibodies to human collagen in subjects with selective IgA deficiency. Clin Exp Immunol 1973; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/80\">",
"      Gulez N, Karaca NE, Aksu G, Kutukculer N. Increased percentages of autoantibodies in immunoglobulin A-deficient children do not correlate with clinical manifestations. Autoimmunity 2009; 42:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/81\">",
"      Knight AK, Bingemann T, Cole L, Cunningham-Rundles C. Frequent false positive beta human chorionic gonadotropin tests in immunoglobulin A deficiency. Clin Exp Immunol 2005; 141:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/82\">",
"      Rankin EC, Isenberg DA. IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997; 6:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/83\">",
"      Nakamura Y, Obayashi A, Hanabusa M, et al. [A case of lupus erythematosus with isolated IgA deficiency (dysgammaglobulinemia type 3)]. Nihon Naika Gakkai Zasshi 1971; 60:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/84\">",
"      Yewdall V, Cameron JS, Nathan AW, et al. Systemic lupus erythematosus and IgA deficiency. J Clin Lab Immunol 1983; 10:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/85\">",
"      Kutimur S, G&uuml;lmezolu E. [Selective IgA deficiency in patients with systemic lupus erythematosus and rheumatoid arthritis]. Mikrobiyol Bul 1985; 19:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/86\">",
"      Maeda M, Kitamura Y, Takata M, et al. [A case of systemic lupus erythematosus demonstrating basal ganglia calcifications, coronary stenosis and selective IgA deficiency]. Nihon Naika Gakkai Zasshi 1986; 75:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/87\">",
"      Kanoh T, Nishimura T, Tokunaga Y. [A case of 21-year-old man with selective IgA deficiency, complicated with systemic lupus erythematosus and papillary adenocarcinoma of thyroid gland]. Nihon Naika Gakkai Zasshi 1987; 76:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/88\">",
"      Rifle G, Bielefeld P, Chalopin JM, et al. Selective IgA deficiency and systemic lupus erythematosus. Ann Med Interne (Paris) 1988; 139:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/89\">",
"      Pelkonen P, Savilahti E, M&auml;kel&auml; AL. Persistent and transient IgA deficiency in juvenile rheumatoid arthritis. Scand J Rheumatol 1983; 12:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/90\">",
"      Badcock LJ, Clarke S, Jones PW, et al. Abnormal IgA levels in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/91\">",
"      Mano T, Kawakubo A, Yamamoto M. Isolated IgA deficiency accompanied by autoimmune thyroid disease. Intern Med 1992; 31:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/92\">",
"      Konstantopoulos K, Tsianateli T, Adamidis S, et al. Selective IgA deficiency in a patient with Hashimoto's thyroiditis. Case report. Ups J Med Sci 1996; 101:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/93\">",
"      Ginsberg A, Mullinax F. Pernicious anemia and monoclonal gammopathy in a patient with IgA deficiency. Am J Med 1970; 48:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/94\">",
"      Liblau R, Fischer AM, Shapiro DE, et al. The frequency of selective IgA deficiency in myasthenia gravis. Neurology 1992; 42:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/95\">",
"      Torrelo A, Espa&ntilde;a A, Balsa J, Ledo A. Vitiligo and polyglandular autoimmune syndrome with selective IgA deficiency. Int J Dermatol 1992; 31:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/96\">",
"      Claman HN, Merrill DA, Peakman D, Robinson A. Isolated severe gamma A deficiency: immunoglobulin levels, clinical disorders, and chromosome studies. J Lab Clin Med 1970; 75:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/97\">",
"      Sandler SG, Zlotnick A. IgA deficiency and autoimmune hemolytic disease. Arch Intern Med 1976; 136:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/98\">",
"      Hobbs JR. Immune imbalance in dysgammaglobulinaemia type IV. Lancet 1968; 1:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/99\">",
"      Claman HN, Hartley TF, Merrill D. Hypogammaglobulinemia, primary and secondary: immunoglobulin levels (gamma-G, gamma-A, gamma-M) in one hundred and twenty-five patients. J Allergy 1966; 38:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/100\">",
"      Kawasaki Y, Suzuki J, Onishi N, et al. IgA deficiency and membranous glomerulonephritis presenting as nephrotic syndrome. Pediatr Nephrol 2005; 20:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/101\">",
"      Huang JB, Yang WC, Hu CC, et al. IgA deficiency with membranous glomerulonephritis: a case report and review. J Nephrol 2003; 16:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/102\">",
"      John M, Lam M, Latham B, et al. Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis. Pathology 2000; 32:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/103\">",
"      Liblau RS, Caillat-Zucman S, Fischer AM, et al. The prevalence of selective IgA deficiency in type 1 diabetes mellitus. APMIS 1992; 100:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/104\">",
"      Smith WI Jr, Rabin BS, Huellmantel A, et al. Immunopathology of juvenile-onset diabetes mellitus. I. IgA deficiency and juvenile diabetes. Diabetes 1978; 27:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/105\">",
"      Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/106\">",
"      Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/107\">",
"      Cataldo F, Marino V, Bottaro G, et al. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997; 131:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/108\">",
"      Asada Y, Isomoto H, Shikuwa S, et al. Development of ulcerative colitis during the course of rheumatoid arthritis: Association with selective IgA deficiency. World J Gastroenterol 2006; 12:5240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/109\">",
"      Manfredi R, Coronado OV, Marinacci G, et al. Chron's disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. Scand J Infect Dis 2004; 36:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/110\">",
"      Iizuka M, Itou H, Sato M, et al. Crohn's disease associated with selective immunoglobulin a deficiency. J Gastroenterol Hepatol 2001; 16:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/111\">",
"      Curzio M, Bernasconi G, Gullotta R, et al. Association of ulcerative colitis, sclerosing cholangitis and cholangiocarcinoma in a patient with IgA deficiency. Endoscopy 1985; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/112\">",
"      Joo M, Shim SH, Chang SH, et al. Nodular lymphoid hyperplasia and histologic changes mimicking celiac disease, collagenous sprue, and lymphocytic colitis in a patient with selective IgA deficiency. Pathol Res Pract 2009; 205:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/113\">",
"      Pytrus T, Iwaczak B, Iwaczak F. [Nodular lymphoid hyperplasia--underestimated problem of gastrointestinal tract pathology in children]. Pol Merkur Lekarski 2008; 24:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/114\">",
"      Piacik M, Rydzewska G, Pawlik M, et al. Diffuse nodular lymphoid hyperplasia of the gastrointestinal tract in patient with selective immunoglobulin A deficiency and sarcoid-like syndrome--case report. Adv Med Sci 2007; 52:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/115\">",
"      Atarod L, Raissi A, Aghamohammadi A, et al. A review of gastrointestinal disorders in patients with primary antibody immunodeficiencies during a 10-year period (1990-2000), in children hospital medical center. Iran J Allergy Asthma Immunol 2003; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/116\">",
"      Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/117\">",
"      Sandler SG. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 2006; 46:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/118\">",
"      Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 1975; 15:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/119\">",
"      Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/120\">",
"      Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 1988; 47:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/121\">",
"      Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev 1995; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/122\">",
"      Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology 2004; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/123\">",
"      Hammarstr&ouml;m L, Persson MA, Smith CI. Anti-IgA in selective IgA deficiency. In vitro effects and Ig subclass pattern of human anti-IgA. Scand J Immunol 1983; 18:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/124\">",
"      Bj&ouml;rkander J, Hammarstr&ouml;m L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/125\">",
"      de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000; 20:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/126\">",
"      Lilic D, Sewell WA. IgA deficiency: what we should-or should not-be doing. J Clin Pathol 2001; 54:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/127\">",
"      Chowdary P, Nair D, Davies N, et al. Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies. Blood Coagul Fibrinolysis 2010; 21:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/128\">",
"      Brown R, Nelson M, Aklilu E, et al. An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti-IgA) and IgA deficiency. Transfusion 2008; 48:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/129\">",
"      Yuan S, Goldfinger D. A readily available assay for anti-immunoglobulin A: is this what we have been waiting for? Transfusion 2008; 48:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/130\">",
"      Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/131\">",
"      McGowan KE, Lyon ME, Butzner JD. Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic. Clin Chem 2008; 54:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/132\">",
"      Murphy EA, Morris AJ, Walker E, et al. Cyclosporine A induced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol 1993; 20:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/133\">",
"      Gilhus NE, Aarli JA. The reversibility of phenytoin-induced IgA deficiency. J Neurol 1981; 226:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/134\">",
"      Ruff ME, Pincus LG, Sampson HA. Phenytoin-induced IgA depression. Am J Dis Child 1987; 141:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/135\">",
"      Talesnik E, Rivero SJ, Gonz&aacute;lez B. Serum IgA deficiency induced by prolonged phenytoin treatment. Rev Invest Clin 1989; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/136\">",
"      Joubert PH, Aucamp AK, Potgieter GM, Verster F. Epilepsy and IgA deficiency--the effect of sodium valproate. S Afr Med J 1977; 52:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/137\">",
"      Kato Z, Watanabe M, Kondo N. IgG2, IgG4 and IgA deficiency possibly associated with carbamazepine treatment. Eur J Pediatr 2003; 162:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/138\">",
"      Maeoka Y, Hara T, Dejima S, Takeshita K. IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Epilepsia 1997; 38:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/139\">",
"      Ibel H, Feist D, Endres W, Belohradsky BH. [D-penicillamine-induced IgA deficiency in the therapy of Wilson's disease]. Klin Padiatr 1990; 202:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/140\">",
"      G&ouml;tze H. [D-penicillamin-induced IgA-deficiency (author's transl)]. Klin Padiatr 1979; 191:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/141\">",
"      Forrest RD, Bostr&ouml;m H, Dahlberg PA. IgA deficiency during penicillamine treatment. Br Med J 1977; 1:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/142\">",
"      van Riel PL, van de Putte LB, Gribnau FW, de Waal RM. IgA deficiency during aurothioglucose treatment. A case report. Scand J Rheumatol 1984; 13:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/143\">",
"      Suzuki T, Okada J, Kashiwazaki S. Selective IgA deficiency developed during treatment of scleroderma kidney with captopril. J Rheumatol 1988; 15:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/144\">",
"      Hammarstr&ouml;m L, Smith CI, Berg CI. Captopril-induced IgA deficiency. Lancet 1991; 337:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/145\">",
"      Farr M, Kitas GD, Tunn EJ, Bacon PA. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. Br J Rheumatol 1991; 30:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/146\">",
"      Farr M, Struthers GR, Scott DG, Bacon PA. Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis. Br J Rheumatol 1985; 24:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/147\">",
"      Stanworth DR, Williamson JP, Shadforth M, et al. Drug-induced IgA deficiency in rheumatoid arthritis. Lancet 1977; 1:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/63/24570/abstract/148\">",
"      Seager J. IgA deficiency during treatment of infantile hypothyroidism with thyroxine. Br Med J (Clin Res Ed) 1984; 288:1562.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3963 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24570=[""].join("\n");
var outline_f23_63_24570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL BIOLOGY OF IgA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role in mucosal immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dimeric secretory IgA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IgA subclasses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY OF IgA DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY OF IgA DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Normal B cell development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      B cells in IgA deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Major histocompatibility complex loci associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2767195\">",
"      - Non-HLA associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Associated immune deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Relationship to autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS IN SYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sinopulmonary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal disorders (non-infectious)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nodular lymphoid hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anaphylactic reactions to blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initial laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Patients with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Patients with symptoms of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Drug-induced immunoglobulin disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3963|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/14/4320\" title=\"figure 1\">",
"      Monomeric IgA molecule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/27/13744\" title=\"figure 2\">",
"      Secretory IgA J ch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_63_24571="Glucocorticoid replacement";
var content_f23_63_24571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glucocorticoid doses for physiologic replacement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Physiologic replacement dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        7 to 12 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day IM or IV",
"       </td>",
"       <td>",
"        10 to 24 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day PO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisone acetate",
"       </td>",
"       <td>",
"        9 to 16 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day IM or IV",
"       </td>",
"       <td>",
"        13.5 to 32 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day PO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisolone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3 to 5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day PO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day PO",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscularly; IV: intravenously; PO: per os (by mouth).",
"     <br>",
"      * Recommended doses for daily physiologic replacement of glucocorticoid. The actual optimal dose must be titrated for each patient based on clinical response and growth rate.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24571=[""].join("\n");
var outline_f23_63_24571=null;
var title_f23_63_24572="Summary table";
var content_f23_63_24572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complementary and alternative therapies for rheumatic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapies known not to be a clinical benefit (and therefore not recommended)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apheresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotics (except minocycline for RA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper bracelets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapies not studied (and therefore not recommended)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shark cartilage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cetyl myristeolate (CMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapies with preliminary, incomplete, or inconsistent evidence of benefit but not (yet) adequately studied (and therefore not recommended)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ayurveda",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yoga",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homeopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photopheresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acupuncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsed electromagnetic fields",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral collagan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAMe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet and nutritional regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herbal therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prayer/distant healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manipulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diacerhein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapies generally accepted of proven value (and therfore not really cam) (but recommended with varying degrees of enthusiasm for reasons of culture and/or clinical efficacy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spa/balneotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucosamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mind-body therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish/botanical oils",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bulletin on Rheumatic Diseases. Arthritis Foundation. Copyright &copy; The Arthritis Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24572=[""].join("\n");
var outline_f23_63_24572=null;
var title_f23_63_24573="Protocol dipyridamole stress";
var content_f23_63_24573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Dipyridamole infusion protocol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Muthu Velusamy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24573=[""].join("\n");
var outline_f23_63_24573=null;
var title_f23_63_24574="Gram stain skin lesion 1";
var content_f23_63_24574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain skin lesion 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24574=[""].join("\n");
var outline_f23_63_24574=null;
var title_f23_63_24575="Apical 4 chamber amylodosis";
var content_f23_63_24575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloid cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view from a two dimensional echocardiogram in a patient with amyloidosis shows greately thickened walls of the left ventricle (LV) with an intensely reflective myocardium, a small LV cavity and relatively poor contractility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_63_24575=[""].join("\n");
var outline_f23_63_24575=null;
